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Abstract

In spite of great effort aimed at eradication, the malaria epidemic still claims over
600,000 lives each year, and 50% of the world is at risk of contracting the disease. The
most deadly form of malaria is caused by Plasmodium falciparum, which is spread from
human to human via the female Anopheles mosquito. P. falciparum’s lifecycle, which
includes both sexual and asexual reproduction, facilitates rapid evolution in response to
drug pressure, resulting in the emergence of resistant strains against every antimalarial
medication that has been deployed. There is a great need for new antimalarial drugs.
Chloroquine (CQ), an aminoquinoline drug deployed in the 1940s, was an
inexpensive, effective and safe drug but now has been rendered ineffective throughout
much of the tropical regions due to the emergence of CQ-resistant strains of P.
falciparum. A new class of hybrid drugs, called Reversed-CQs, has been developed by
linking a molecule with a CQ-like moiety to a molecule with a reversal agent (RA)
moiety; an RA is a chemosensitizer that can reverse CQ-resistance. The prototype
Reversed-CQ, PL01, was shown to be effective in vitro against sensitive and resistant P.
falciparum cell cultures, with IC50 values of 2.9 and 5.3 nM, respectively, in comparison
to IC50 values for CQ which were 6.9 and 102 nM, respectively.
In the course of the Reversed-CQ research, PL74 was synthesized with a pyridine
ring replacing the quinoline ring. It was expected that PL74 would display reversal agent
activity but would not display antimalarial activity. However PL74 showed antimalarial
i

activity with IC50 values of 185 and 169 nM in vitro against CQ-sensitive and CQresistant strains, respectively. In the investigation of PL74 it has been found that this
molecule has a pyridinium salt structure, novel to the Reversed-CQ compounds, and
through a structure-activity relationship (SAR) study, it was shown to have activity that
may indicate a mode of action different from the Reversed-CQ compounds. A study of
the literature revealed that pyridinium salt compounds, with some similarity to PL74,
were found to operate as choline analogs inhibiting the biosynthesis of
phosphatidylcholine as their main antimalarial mode of action.
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Chapter 1

Introduction

Malaria is a worldwide problem causing approximately 200 million cases of
illness, resulting in over 600,000 deaths per year.1 The majority of this disease burden is
borne by the sub-Saharan Africa population, and the majority of the global malaria
mortalities are among the children of this region. Nearly 50% of the world’s population
is currently at risk of contracting malaria.1 These statistics show a marked improvement
in the mortality rate from the estimated one million deaths per year from 2000 to 2005.1
However, an analysis of the mortality rates by Christopher Murray and his team at the
Institute for Health Metrics and Evaluation, University of Washington, found that the
death toll due to malaria has been about twice the estimates reported by the World Health
Organization (WHO) for the years of 1980-2008; thus the 2013 WHO statistics may be
an understatement of the situation.2
Malaria has a catastrophic effect on the economics of the endemic regions,
severely hindering social stability and development.3 Malaria and extreme poverty form
a vicious cycle: Malaria causes extreme poverty by causing an unreliable workforce and
deterring investments in the region; extreme poverty makes it impossible to fight
effectively against malaria because of the high costs of public education, vector control,
and treatment. In this way malaria is a history shaper, so it is not coincidental that the

1

map of malaria disease burden is the approximate inverse of the map of the distribution
of wealth (Figure 1.1).

Figure 1.1: The Inverse Relationship of Malaria Burden to Wealth Distribution
Map of Malaria Risk (Top).
The Global Malaria Mapper plotted March, 2014, http://www.worldmalariareport.org.
Map of Gross Domestic Product Per Capita (Bottom).
GDP data from 2005, http://commons.wikimedia.org
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The most alarming part of the malaria situation is that the drugs and insecticides
that have been useful in the past against malaria are losing their effectiveness due to the
development of resistance in both the malaria parasite and the Anopheles mosquito,
which serves as the vector of disease transmission. There is a need for a constant supply
of new tools and thoughtfulness in their use to bring this epidemic under control and
perhaps to the eventual eradication of malaria.

Background
Plasmodium protozoa are the causative parasitic organisms of malaria.4 There are
over 120 different species of Plasmodia, but only five types of malarial parasites (P.
falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi) are commonly found in
humans.4,5 P. falciparum, the most virulent of the five, is the most studied form of
malaria, and the target of this research.
The onset of malaria is generally characterized by flu-like symptoms: fever,
shaking chills, headache, sweats, fatigue, nausea, and vomiting.6 The signature symptom
of a malaria infection is that the febrile symptoms occur in a cyclic pattern. However,
most adults in endemic regions remain asymptomatic during malaria infections.7
Untreated or improperly treated P. falciparum malaria may lead to kidney failure, mental
confusion, coma, pulmonary edema, and death.6
P. falciparum is spread from human host to human host exclusively via the female
Anopheles mosquito.8,9 The Anopheles mosquitoes are nocturnal insects that breed in
standing water, then emerge as fully developed adults within days,9 and mate within one
3

to two days after emergence.10 The female will lay 50 to 200 eggs within two to three
days in tropical climates.10 The female requires blood meals during the egg maturation
process, in which it may ingest the malaria parasite from an infected human or transmit
the parasite.
The lifecycle of P. falciparum (Figure 1.2) requires both a female Anopheles
mosquito host and human host, and includes both sexual and asexual reproduction.
When an infected female Anopheles mosquito bites a human, P. falciparum sporozoites
are released from the mosquito’s salivary glands into the bloodstream of its victim.8
Within a few minutes the sporozoites enter the liver and invade the hepatocytes. The
parasites undergo asexual multiplication in the liver cells, increasing to tens of thousands
over 9 to 16 days, then burst from the liver cells and invade the erythrocytes. The
sporozoites undergo further asexual multiplication in the erythrocytes – resulting in 12-16
merozoites from each sporozoite, eventually rupturing the cells and invading other
erythrocytes. This erythrocytic stage cycles every 48 hours for P. falciparum, P. vivax
and P. ovale; every 72 hours for P. malariae; and every 24 hours for P. knowlesi.7,11 In
response to this periodic rupturing, the host’s immune system causes the cyclic fevers and
chills which are the signature clinical manifestations of malaria infections. Some of the
merozoites differentiate into male and female gametocytes but remain in an immature
form while in the human host. However, if these gametocytes are taken up as a female
Anopheles mosquito takes a blood meal and enter the gut of the mosquito, the male
gametocyte is able to mature and fertilize the female gametocyte, creating an oocyte
which may be the beginning of a new strain of P. falciparum. Within the oocyte,
4

Figure 1.2: Malaria Lifecycle
Repurposed graphic combining figure from Malaria Vaccine Initiative (www.malariavaccine.org) and
picture by Mr. Stephen Morrison (European Press Agency)

sporozoites are formed by asexual reproduction. The oocyte will eventually burst open
and release the sporozoites. These sporozoites migrate to the salivary glands of the
mosquito and are released into human hosts during blood meals. Parasite development in
the mosquito, from the time of ingestion to transmission, is 10 to 21 days.9
5

When the human host takes an antimalarial drug during the life cycle of the
parasite, the hope is to kill all the parasites and thereby end the malaria sickness.
However, if the drug is not potent enough, or if it is not taken over a long enough time, a
few parasites may survive, some of which might happen to have a variation in their
genome that gives them an enhanced ability to survive and continue to replicate, allowing
the emergence of new strains. When the genomes of those survivors are crossed with the
genomes of other survivors during sexual reproduction, new parasites with adaptations
that can withstand the antimalarial action of a drug may emerge. When sufficient and
widespread resistance has emerged against a specific drug, then that drug is deemed no
longer useful in that area.

Strategies for Control
In developing a strategy to control and eventually eradicate malaria, three areas of
response emerge: vector controls, vaccines, and antimalarial drugs.1 No one method of
the control is adequate, but efforts in all three areas are reducing the number of deaths
due to malaria.
Vector Controls: There are over 40 species of Anopheles mosquitos that have the
abundance, longevity, capacity and preference for human blood to make them a
significant threat.12 Among these species there are diverse habitat and feeding
requirements, making it difficult to find just one single answer to control the mosquito
populations. Several approaches are in use to reduce the mosquito populations including
eliminating or treating standing water to lessen the available breeding grounds for larva.
6

Such treatments include the introduction of larva-eating fish or treating the waters with
Bacillus thuringiensis isrealensis and Bacillus sphaericus, bacterial pathogens selective
for mosquito larva.12 Insecticides are employed to reduce the adult population of
mosquitoes, however, the mosquitos are developing resistance to the insecticides so that
they are becoming less potent over time.12
An obvious way to interrupt the malaria transmission cycle is to keep mosquitoes
from biting humans. A way to accomplish this goal is by protecting humans with
insecticide treated bed nets (ITNs), especially during the nighttime when the Anopheles
mosquitoes are most active. When surveying populations at risk, it was self-reported that
55% of households own at least one ITN, 33% own an adequate number to protect all the
members of the household, and 86% of ITN owners diligently use them.1 The WHO
estimates, admittedly crudely, that there are over 300 million ITNs currently in service,
but at least 450 million are needed for adequate coverage.1 The useful life expectancy of
an ITN is three years; one third of the ITNs retiring each year makes it difficult to build
to the needed level of availability.1 The use of ITNs has been shown to reduce mortality
rates for children (under the age of 5) by approximately 16%, in a 2002 study in western
Kenya.13 Even with such a remarkable achievement, vector controls alone are not
adequate to control, eliminate, or eradicate malaria.
Vaccines: A vaccine against malaria would be a very useful tool to combat
malaria in endemic areas. Vaccines ideally educate the immune system to provide longterm immunity against disease. Although several successful vaccines have been
produced against viruses such as smallpox and measles, the antimalarial vaccines that are
7

now in human trials are the first vaccines that have been produced with a degree of
success against any parasite. As discussed next, the success is modest.
A vaccine against a parasite is more challenging than an antiviral vaccine because
the parasite potentially presents thousands of antigens to the human immune system,
changes forms throughout its life stages in the human host, evolves to render the immune
responses ineffective (as do viruses), and spends much of its lifecycle inside host cells.14
On the other hand, there are indicators that a malaria vaccine may be feasible: the
occurrence of natural immunities developed in response to severe disease, the finding that
irradiated sporozoites introduced into humans provided some protection from subsequent
challenges, and the finding that immunity can be passively transferred by injecting
antibodies from a host that has acquired immunity.14,15
A notable accomplishment of the vaccine research to date is the Glaxo Smith
Kline RTS,S/AS01, a vaccine candidate that acts against liver stage malaria. In Phase III
clinical trials, RTS,S/AS01 has shown to reduce the incidence of clinical disease by 55%
for the year following vaccination.1,16
The PfSPZ vaccine comprised of non-replicating, whole P. falciparum
sporozoites being developed by Sanaria has recently completed a Phase I clinical trial;
the early findings show that the vaccine was well tolerated by the study participants, and
that 12 out of 15 were protected from a challenge infection administered three weeks
later.15 Although these results look promising, the cost and time investment to produce
whole organism vaccines makes this a less desirable vaccine for widespread use.17

8

Pfs25-EPA is a transmission-blocking vaccine that acts against antigens expressed
on the surface of the gametocyte, the sexual form of the parasite that remains in the blood
stream.18,19 When the gametocyte is taken up by the mosquito it is unable to reproduce.
The drawback of this approach is that it carries no direct protective benefit for the
vaccinated person and requires widespread employment before any benefit would be
realized.
There are several other vaccine candidates that are being pursued that are much
earlier in the development process; they are estimated to be five to ten years away from
clinical trials.1 Among these candidates are blood stage infection and transmission
blocking vaccines, all showing promise of usefulness.1 However, even after decades of
research and development, we still do not have a vaccine that is ready for widespread use.
Our inability to eradicate the mosquito vector quickly, or to develop a wide-spectrum,
long-lasting vaccine quickly leaves us with the alternative of fighting pandemic active
infections with chemotherapeutic drugs.
Antimalarial Drugs: Quinine (Figure 1.3), an extract from Cinchona bark, has
served as a leading antimalarial for hundreds of
years.20 It was used in the unextracted form
since the 1600s, and was isolated and named in
1817 by French researches Pierre Pelletier and
Joseph Caventou. In 1964, Robert Woodward
and coworkers achieved the first total synthesis
Figure 1.3: Structure of Quinine

of quinine.21,22 Quinine was very effective for
9

the treatment of malaria caused by P. falciparum, and it remained the frontline drug until
the 1940s when chloroquine (CQ) took over. Although quinine is effective, it has many
unpleasant, but usually temporary, side effects. It causes sweatiness, tinnitus, vision
problems, hearing impairment, confusion, headaches, rashes, abdominal pain,
photosensitivity, vertigo, dysphoria, nausea, vomiting, and diarrhea.20
In 1946, CQ (Figure 1.4) was introduced as an antimalarial. CQ was synthesized
and studied as an antimalarial beginning in 1934 by Hans Andersag at Bayer I.F.
Farbenindustrie A.G. Laboratories in Eberfeld, Germany.23 However, CQ was
abandoned in favor of Atabrine,
another drug candidate, because of
its slight toxicity in birds, and so CQ
was overlooked until 1946 when it
was recognized for its safe and
effective antimalarial properties by

Figure 1.4: Structure of Chloroquine (CQ)

British and US scientists. CQ
quickly became the main drug used for malaria treatment and prevention because it was
effective in a few doses, had mild side effects, was safe even for infants and pregnant
women, and was very inexpensive. It was hoped that this drug, along with mosquito
control, would be the means to eradicate the disease worldwide. However, by the 1950s
CQ-resistant strains of malaria emerged in South America and Southeast Asia, then
quickly spread throughout the world except for Africa. In the 1980s CQ-resistant strains
began to emerge in Africa. Although still used in Africa, CQ has been rendered nearly
10

ineffective in much of the world, and its continued use will certainly promote the
evolution of CQ-resistant strains of P. falciparum malaria. Discussion of the CQ mode of
action and mechanism of resistance is deferred to a later section of this chapter.
Artemisinin (Figure 1.5), the current lead antimalarial, is a sesquinterpene lactone
with a peroxide bridge. Artemisinin is isolated from the plant, Artemisia annua, and has
been known in traditional Chinese medicine for thousands of years. The earliest mention
of its use dates back to 168 B.C., but the first mention of its use as an antimalarial was by
Wenbing Tiaohian in 1798.24 It was forgotten, then rediscovered in 1972 by Tu Youyou,
who was evaluating traditional Chinese
medicines for treating malaria.24 The
practical use of artemisinin as an
antimalarial agent is impaired by its
insolubility in both water and oil, poor
efficacy by oral administration, and the rate
of recrudescence in treated patients. To

Figure 1.5: Structure of Artemisinin

improve solubility and bioavailability, semisynthetic analogs were devised. Three that are currently in use are artemether, artesunate,
and dihydroartemisinin (Figure 1.6). The artemisinins are very potent antimalarials that
are effective against both sexual and asexual forms of the parasite; in addition, they are
very fast acting drugs, killing the malaria parasite within minutes and clearing the blood
of 98% of infection with a single dose. However, artemisinins have very short half-lives
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Figure 1.6: Structures of Artemisinin-Based Combination Therapies (ACTs)

in the body, which makes it difficult to dose for continuity of coverage over a span of the
parasite’s lifecycle.25
The mode of action for the artemisinins is still under investigation. It is known
that the peroxide bridge is essential to the activity of the artemisinins: when one peroxide
12

oxygen is replaced by a carbon, the resulting analog is inactive.26 The mode of action of
the artemisinins is via a free radical mechanism, shown by the fact that free radical
scavengers have an antagonistic effect on the antimalarial activity of these drugs.27,28
Free iron and/or heme-bound iron activate the homolytic cleavage of the endoperoxy
bridge of the artemisinins to form a radical. The need for an iron-rich environment for
activation may be the reason that this drug acts selectively against the parasite. The free
radical may act as an oxy radical or rearrange to a carbon centered radical.29 Several
possible actions of the radical have been suggested, including acting as a strong reducing
agent, alkylating heme, and/or alkylating proteins.30
Because of the increasing problem of resistance against antimalarial therapies, the
WHO recommended in 2005 that all countries experiencing P. falciparum drug resistance
use drugs in combination therapies, preferably artemisinin-based combination therapies
(ACTs).31 The rationale for ACTs is that it combines drugs with different modes of
action against the same parasite life stage, making it statistically improbable that mutant
strains would develop resistance mechanisms at both sites of action, thereby killing more
(or all) of the parasites of an infection, and thereby protecting against the development of
resistance to either of the drugs.
In the design of an ideal combination therapy there are several pharmacodynamic
and pharmacokinetic factors to consider. It is important that these drugs be synergistic
(or at least non-antagonistic), and have different modes of action against the same life
stage, providing a parasite killing efficacy of nearly 100% per cycle.32 It is important that
the drugs are a good pharmacokinetic match so that they both keep constant pressure on
13

the parasite during the whole course of treatment in order to protect both drugs against
the development of resistance. The combination needs to be delivered in a simple
regimen to facilitate patient compliance, and ideally be able to maintain a therapeutic
level for 3 cycles, which is 6 days for P. falciparum malaria. It is also preferred that the
partner drugs have moderate half-lives so the time the drugs reside in the patient at subtherapeutic levels is minimized, reducing the opportunity for resistance to develop.
The ACTs that are currently in use are artemether/lumefantrine,
artesunate/amodiaquine, artensunate/mefloquine, artensunate/sulfadoxinepyrimethamine, and dihydroartemisinin/piperaquine (Figure 1.6). Lumetantrine,
amodiaquine, mefloquine and piperaquine are active against the erythrocytic stages. The
modes of action for these drugs are not fully elucidated, but all are suspected to inhibit
hemozoin formation, much like CQ, discussed below.33 The sulfadoxine-pyrimethamin
have a well- defined mode of action: inhibiting the enzymes involved in parasitic folic
acid synthesis.34 These partner drugs all have half-lives longer than the artemisinins.33
In spite of the precaution of a policy of combination therapy, P. falciparum strains
that are resistant to the artemisinins have emerged both in the Cambodia-Thailand border
and at the Northern Thailand-Myanmar border.35 Artemisinin resistance is so far defined
by the slow clearing of the parasites and is specifically related to the ring-stage parasite.35
These first signs of resistance are quite alarming in the absence of another lead drug to
replace the artemisinins as the next cornerstone of malaria chemotherapy. In addition,
resistance has emerged to each of the partner drugs currently used in combination with
the artemisinins.
14

In addition to the curative therapies, intermittent preventive therapy (IPT) is used
to protect the populations that are most at risk from malaria. These populations are
pregnant women, infants, and children, in high transmission areas. The risk of severe P.
falciparum malaria is increased for pregnant women and associated with a mortality rate
of nearly 50%.7 At the time of giving birth, there is evidence of malaria in 25% of the
women.36 The incidence of babies with low birth weight is twice that of births for noninfected mothers and the incidence for infant mortality is markedly increased for low
birth weight babies.36 Seventy percent of the annual death toll for malaria is comprised
of children that are under the age of 5 years old in high transmission areas.1
The combination of sulfadoxine-pyrimethamine has been the IPT of choice since
the mid-1990s.37 Several IPT studies from since the mid-1990s to 2008 have shown
decrease in both the incidence of malaria and the mortality rate for stable and seasonal
high transmission areas.36-41 However, studies over the last 10-12 years, in Malawi,
Tanzania, Uganda and Mozambique all show the lessening or loss of benefit from IPT
with sufladoxine-pyrimethamine because of the growing resistance against the drugs.37,40
Another need for prophylactic drugs is among travelers who will be going into
high transmission areas. It is estimated that currently there are over a billion international
border crossings per year.42 It is important to protect travelers for their sake, but with
such a high volume of travelers it also important to keep malaria from spreading to new
areas.

15

A wider range of drugs is available to travelers than can be used in the endemic
countries based both on the cost and the pharmacokinetics of the drug. Prophylactic
drugs currently in use are shown in Figure 1.7.43,44 Travelers have the advantage of being
able to both build to and wane from therapeutic levels while they are not under the threat
of malaria infection; malaria infections that occur when drugs are at a sub-therapeutic
level breed resistance to the drug. The causal malaria prophylactic drugs act against the
liver-stage of the
parasites lifecycle and
the suppressive drugs
act against the blood
stage of the parasite.45
The drug choice and
regimen are customized
to each traveler based
on the details of their
itinerary and the
Figure 1.7: Prophylactic Drugs for Travelers

availability of
immediate medical

support during their trip. The drugs are continued for one to three weeks after exiting the
endemic regions to facilitate total clearance of the parasite. Even with a customized
regimen and good compliance, prophylactic drugs are only 75 - 95% effective for no
incidence of malaria infection.44
16

A Closer Look at Chloroquine Mode of Action, and Resistance to Chloroquine
During the blood stage of malaria, P. falciparum imports and digests 60-80% of
the hemoglobin from the cytoplasm of the host’s red blood cell.46 The four embedded
heme groups in hemoglobin are freed and cannot be degraded by the parasite. The
accumulation of free heme in the digestive vacuole (DV) would be fatally toxic to the
parasite.47 To avoid the toxic effects, the free heme is crystallized into insoluble, densely
packed hemozoin, as shown in Figure 1.8.
The mechanism for hemozoin formation is not fully understood. Studies of the in
vitro formation of β-hematin, a compound that is spectrometrically and
crystallographically the same as hemozoin and thus presumed to be identical to
hemozoin,47 have shown the following: Nucleation of β-hematin occurs spontaneously at
physiological temperature and acidic pH of the DV but at a rate too slow to be effective
as the detoxification pathway.48 It has been found that both histidine rich protein and
lipids promote the nucleation of β-hematin.48 Once nucleation has occurred, the βhematin formation process is autocatalytic.47
Recently it was discovered that lipid nanospheres are present in the DV49 and they
are the site of hemozoin formation.50,51 Further studies have shown that a two-phase
system, such as octanol-water or pentanol-water, promotes hemozoin formation over the
rates seen in water alone, and over the rates seen in octanol or pentanol alone.47 This
suggests that the interface of the two-phase system catalyzes the formation of hemozoin.
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Figure 1.8: Structure of Hemozoin
Molecular and Biochemical Parasitology 2008, 157, 128

The currently-accepted mode of action of CQ is the inhibition of hemozoin
formation, thus subjecting the parasite to the toxic effects of the free heme.52 CQ has two
protonatable nitrogens; the quinolyl nitrogen has a pKa of 9.8 and the tertiary sidechain
nitrogen has a pKa of 8.6.53 CQ in the uncharged state is membrane-permeable and
diffuses into the parasite’s DV (Figure 1.9).52 In the acidic DV the CQ becomes doubly
charged and complexes with the free heme.54 Both the high proton concentration and the
free heme shift the equilibrium toward CQ in the DV.54 CQ accumulates in the DV to
approximately 6000 times more than the concentration in uninfected red blood cells.55
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Figure 1.9: Chloroquine Accumulation
Graphic inspired by Hladky, S. B. Chloroquine Accumulation, http://www.phar.cam.ac.uk, 2006.
pKa values from Journal of Medicinal Chemistry, 2008 June 26; 51(12): 3466.

Through cell fractionation methods measuring the iron and hemozoin concentrations, it
has been shown that there is a dose-dependent inhibition of hemozoin formation by CQ,
which results in the buildup of free heme in the malaria cell and tightly correlates to the
parasite death.56 Also, tunneling electron microscope images show the disruption of
hemozoin crystallization by CQ.56 Thus, CQ complexing with heme inhibits the
biocrystallization of hemozoin, which results in the parasite’s death.
In CQ-resistant strains of P. falciparum, it has been shown that CQ accumulation
is four to ten times less in the DV of the parasites than for CQ-sensitive strains.57 From
comparisons between CQ-resistant and CQ-sensitive strains, it was determined that the
primary determinants of CQ-resistance are mutations in the pfcrt gene.58 The pfcrt gene
gives rise to the PfCRT (Plasmodium falciparum CQ resistance transporter) protein, and
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has been shown to transport CQ out of the digestive vacuole.59 The PfCRT protein has
been shown to be located in the DV membrane, and is predicted to have 10
transmembrane domains.60

Reversal Agents
A reversal agent (RA) is a drug that reverses the effect of resistance against
another drug.61 Because of similarities seen in the resistance of P. falciparum and
neoplastic cells, the possibility of reversing the resistance was pursued.59 Verapamil, a
calcium channel blocker, had been useful in reversing drug resistance in neoplastic cell
cultures by inhibiting the active efflux of anticancer drugs. When Verapamil was coadministered with CQ, the IC50 of CQ against CQ-resistant strains was reduced to nearly
the IC50 of the CQ-sensitive strain.59
Several reversal agents
have been found for P.
falciparum, and from these
known reversal agents, a
geometric distribution map of
their common chemical features
was determined through
modeling studies (Figure 1.10).62
This three-dimensional map, or

Figure 1.10: Pharmacophore of Reversal Agents

pharmacophore, based on the

Journal of Chemical Information and Modelling 2002, 42,
(5),1214
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specific set of reversal agents was comprised of two aromatic hydrophobic sites and a
hydrogen bond acceptor site (generally a nitrogen atom located on a side chain two to
three bonds removed from the aromatic sites).62 This pharmacophore can be applied as a
predictor of reversal agent potency for analogous molecules.
Although the demonstration that reversal agents can restore the effectiveness of
CQ was encouraging, using reversal agents as part of a treatment regimen has a major
drawback. The known antimalarial reversal agents are usually drugs designed for nonantimalarial purposes. For example, there are several examples of reversal agents that are
antihistamines, anti-depressants, anti-hypertensives, or anti-psychotics. Because these
drugs were designed to affect other targets, they require a relatively large dose to
accumulate enough in the DV to reverse CQ-resistance. In order to make use of an RA to
restore the activity of CQ, it is necessary to find a way to target the RA to the site of
action in malaria infections.

Reversed-Chloroquines
A solution was proposed to link the reversal agent covalently to a CQ-like moiety,
forming a hybrid molecule, in this case a ‘Reversed-CQ’, that has a dual mode of action
(Figure 1.11).63 The concept was that the CQ-like moiety can act as an antimalarial,
while the reversal agent-like moiety can circumvent the mechanism of resistance; the
covalent linkage between these two moieties ensures that they are both present in the DV
at the same time. It was hoped that a much smaller dose would be needed against CQresistant strains than when they are administered separately, minimizing the toxic effects
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Figure 1.11: Reversed Chloroquine PL01
to the host.63
To test the Reversed-CQ-concept, PL01 was synthesized by Steven Burgess.63
PL01 is constructed to include an imipramine-like moiety (the RA) and a CQ-like moiety.
Imipramine is a known reversal agent and fits the Bhattacharjee pharmacophore.62,64 The
CQ methyl at the side chain C1 chiral center has been shown to be non-essential for
antimalarial activity,65 and thus has not been included in the CQ-like moiety, leading to
an achiral molecule.
The antimalarial effectiveness of PL01 was evaluated by in vitro drug
susceptibility assays against P. falciparum parasites. The assays were conducted using
D6 (a CQ-sensitive strain) and Dd2 (a CQ-resistant strain) P. falciparum cell cultures.
PL01 gave an IC50 that was slightly lower than for CQ against the CQ-sensitive strain,
and nearly a 20-fold increase in activity for the CQ against the CQ-resistant strain,
making this value nearly that of the IC50 against the CQ-sensitive strain. This indicates
that PL01 is active against the CQ resistance mechanism present in the Dd2 CQ-resistant
strain. The reduced IC50 against CQ-sensitive strain relative to that of CQ may suggest
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low-level resistance in the D6 CQ-sensitive strain, or may be a reflection of a fitness level
difference between the strains.66
The antimalarial effectiveness of PL01 was also evaluated in an in vivo study in
mice. This study demonstrated that 64 mg/kg/day for 4 days suppressed over 99% of the
P. chabaudi (a rodent malaria commonly used as a model organism).67 Poor
bioavailability of PL01 was expected because of the drug’s lipophilic nature as estimated
by clogP (the calculated log of the partition coefficient between n-octanol and water).
The clogP of PL01 is 8.9, which is much higher than the 5.1 clogP of CQ.63 Lipinski’s
Rule of Fives, a set of rules to estimate the solubility and permeability of investigational
compounds, indicates that a logP of less than five is favored for a compound to be orally
active.68 However, the mouse result demonstrates that PL01 has some oral
bioavailability, and also has in vivo antimalarial activity.
The binding constant of PL01 to the heme was evaluated by UV-vis titration.63 It
was found that the Reversed-CQ-heme2 binding constant at pH 5.7 was about the same as
for CQ-heme2 at the same pH, confirming
that the modifications to the CQ-like
moiety and the addition of reversal agentlike moiety do not interfere with the
binding of heme.
PL02 (Figure 1.12) was designed
on the same concept of linking a CQ-like
Figure 1.12: Reversed CQ Molecules

molecule to an RA-like molecule.

Synthesized by Steven Burgess
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However instead of using a known reversal agent, diphenylmethylpiperazine was chosen
such that it possesses the essentials of the RA pharmacophore as defined by the
Bhattacharjee study62 but without its “tricyclic antidepressant” structure. In in vitro drug
susceptibility assays against P. falciparum, PL02 gave a low IC50 against both CQsensitive D6 and CQ-resistant Dd2. In fact, the P. falciparum IC50 values were slightly
lowered (improved) over the results for PL01. Heme binding studies revealed nearly the
same association constant as for PL01.

PL74: A Molecule of Interest
PL74 (Figure 1.13 for amine-linkage target structure) was originally synthesized
by Steven Burgess to be a PL02 analog without antimalarial activity, in order to test the
RA activity.69 In a structure activity relationship (SAR) study of aminoquinolines, Egan
concluded that the quinoline ring forms a complex with heme largely based on π-π
interaction.54 Egan also concluded that the 7-chloro substituent on the quinoline ring is
the minimum critical feature for
β-hematin inhibition.54 In the
change from PL02 to PL74 both
the chlorine and half of the
quinoline were removed. It was
postulated that this modification
should abolish β-hematin
inhibition and diminish the π-π

Figure 1.13: Amine-Linkage Structure for PL74
Proposed by Steven Burgess
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interaction with heme.
However, in vitro drug susceptibility assays were performed for PL74 against two
cell cultures: D6 (a CQ-sensitive culture) and Dd2 (a CQ- resistant culture). It was
found that the compound had an IC50 for D6 (CQ-sensitive) of 185 nM and an IC50 for
Dd2 (CQ-resistant) of 169 nM.69 These results are modest in comparison with the
prototype Reversed-CQ but far better than anticipated (Figure 1.14, Table 1.1).
Optical spectroscopic studies were carried out to determine equilibrium binding
and β-hematin inhibition.70 For equilibrium binding, addition of the CQ and the PL
compound showed a clear perturbation of the heme dimer absorption spectrum upon
binding. The 2:1 Affinity Model, in which the heme dimer bonds to one drug molecule
(previously reported by Jane Kelly), can be used to determine the association constant
(Ka) from the dose-response curve.71 The Ka for PL74 was determined to be 5,000, a
five-fold reduction from the Ka of CQ. Again, the value of Ka is small in comparison to
CQ, PL01, and PL02--but still indicates that PL74 can associate with the heme dimer.
For the β-hematin inhibition assay a solution of heme, Tween 20, and sodium
acetate buffer (pH 4.8) was used to mimic the digestive vacuole environment.70 After 24
hours incubation of this solution, there was a complete loss of absorbance in the Soret
range, indicating the absence of measurable quantities of free heme. On repeat with the
addition of active PL compounds, the Soret band absorbance was preserved, indicating
the presence of free heme, thus indicating the inhibition of β-hematin formation. The
inflection point of the sigmoidal dose-response curves indicates the IC50 of β-hematin
formation. The IC50 for PL74 was found to be 290 µM, a value more than 10x the IC50
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for CQ, but still far greater than expected. See Table 1.1 for comparison of the β-hematin
inhibition IC50 values for CQ, PL01, PL02, and PL74.

Figure 1.14: Structures of CQ and Selected PL Compounds
Table 1.1: In vitro Drug Susceptibility, Binding, and β-Hematin Inhibition Assay
Results
In vitro Drug Susceptibility Assay

UV Titration Studies

IC50 (nM) D6
(CQ-sensitive)

IC50 (nM) Dd2
(CQ-resistant)

Association
Constant (Ka)

IC50 (µM)
β-Hematin
Inhibition

CQ

6.9

102

249,000

24

PL01

2.9

5.3

110,000

9.0

PL02

1.0

3.6

300,000

2.5

PL74

185

169

50,000

290
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The unexpected activity of PL74 was intriguing and warranted further
investigation. This dissertation is a record of the investigation. Through these studies it
was found that PL74 does in fact have some unique features and possibly a mode of
antimalarial action different from the Reversed-CQ molecules. As shown in the
following chapters, both the structure of the molecule and its proposed mechanism of
action needed revision.
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Chapter 2

The Structure of PL74

PL74 and its proposed amine-linkage structure (Figure 2.1) were a paradox in
some ways. Not only did PL74 have stronger antimalarial activity than expected from
the proposed amine-linkage structure, but its solubility and reactivity were also
perplexing. PL74 was not soluble in water above pH 5.5. Attempts at syntheses via
routes similar to those used for the RCQs were rarely successful. These observations led
me to propose a re-evaluation of the structure and propose an alternative pyridinium salt
structure (Figure 2.1).
The proton NMR peak assignments of the 1D spectrum acquired in methanol-d4
originally made for the amine-linkage structure of PL74 are shown in Figure 2.2,
Spectrum A. These assignments were
made based on consideration of
analogous peak assignments for the RCQ
molecules. The amine-linkage structure
is consistent with the chemical shifts,
integral values, and signal splitting seen
in the spectrum. However, a careful
examination of the proton NMR spectra
in both methanol-d4 and DMSO-d6 gives

Figure 2.1: Proposed Structures for PL74
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an indication that PL74 might be a pyridinium salt; the NOESY spectrum in methanol-d4
gives the conclusive evidence. For further assurance of the pyridinium structural
determination, the PL74 spectra were evaluated in contrast to the analog PL343 spectra;
PL343 is not a pyridinium salt but has an amine linkage. My interpretation of the 1D and
2D 1H NMR spectra of PL74 is as follows.
In the 1H NMR spectrum acquired in methanol-d4 (Figure 2.2, Spectrum A), five
peaks appear in the aromatic region. The AA'BB' spin system of the pyridine ring
protons give rise to signals at 8.03 and 6.79 ppm. Due to the electronegativity of the
nitrogen, the two protons closest to the aromatic nitrogen are the most deshielded of the
aromatic protons, and so give rise to the peak at 8.03 ppm. The shielding from the
electron density donated by the amine substituent shifts the second doublet upfield to
6.79 ppm. The 10 phenyl protons give rise to three signals at 7.41, 7.25, and 7.16 ppm,
which integrate to 4H, 4H, and 2H, respectively, relative to the 2H integration of the
pyridine doublet at 8.03 ppm. There are also five peaks that appear in the aliphatic region
in this spectrum. The methine proton signal is a singlet at 4.20 ppm and has a relative
integral value of 1H. The ethyl linker chain gives rise to two triplets at 4.15 ppm and
2.74 ppm, both with relative integration of 2H. The eight piperazine ring protons are
averaged by the chair-flipping of the ring and result in broad signals at 2.53 and 2.38
ppm. The methylene next to the piperazine nitrogen has a micro-environment most like
the piperazine and so is assigned to the upfield triplet peak at 2.74 ppm. The amine
protons are not seen in methanol-d6 because they are exchanged with deuterium from the
solvent. The one indication in this spectrum that PL74 is, in fact, the pyridinium salt is
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Figure 2.2: Proton NMR Spectra of PL74
Spectrum A: 1-d spectrum in methanol-d4; Spectrum B: 1-d spectrum in DMSO-d6
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the methylene peak’s chemical shift, downfield to 4.15 ppm, suggesting that the protons
are strongly deshielded; the position next to the aromatic quaternary nitrogen would be
expected to lead to a strong deshielding effect, while the amine of the amine-linkage
structure would not.
There are two indications of the pyridinium salt structure seen in the DMSO-d6 1H
proton spectrum (Figure 2.2: Spectrum B). The amine protons, which would not
exchange with the solvent, give rise to a signal at 8.10 ppm. This amine peak overlaps
with the downfield pyridinium peak, but the two peaks together have the relative
integration of 4H; the 2H increase to the integral value indicates that the amine is a
primary amine, as in the pyridinium salt structure, instead of the secondary amine, as in
the amine-linkage structure. In addition, when the amine proton signal appears in the
spectrum, its nuclear spin will cause additional splitting on the vicinal protons; in the
proposed structure, a splitting of the triplet to a doublet of triplets from this additional
coupling would be seen. The absence of the additional splitting on the peak at 4.15 ppm
(peak c in Figure 2.2B) is a strong indication against the initially proposed structure.
A nuclear Overhauser effect spectroscopy (NOESY) experiment measures the
transfer of energy through space between protons that are within about 5 Å of each other;
the closer the protons are in space the stronger the effect will be. In the 2D NOESY
spectrum (Figure 2.3) a cross peak, indicating energy transfer, correlates the methylene
peak at 4.15 ppm to the pyridine peak at 8.03 ppm (indicated by the purple arrow in
Figure 2.3). There is no cross peak from the methylene peak at 4.15 ppm to the pyridine
peak at 6.79 ppm, indicating that these peaks are further apart (region marked by purple
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Figure 2.3: NOESY Spectrum of PL74 in Methanol-d4

(Purple arrow indicates cross peak between aromatic peak a and methylene peak c. Purple box around
region where a cross peak between peak b and methylene peak c would occur.)

box in Figure 2.3). This clearly indicates that the pyridinium structure is the molecule
actually synthesized by Burgess.
In the spectra of PL343 (Figures 2.4 and 2.5), the five expected observations are
seen for a molecule with an amine linkage between the 4-aminopyridine and the
headgroup. In the 1H-spectrum recorded in methanol-d4, Figure 2.4A, the triplet arising
from the methylene near the amine is shifted further upfield to 3.51 ppm, midway
between the piperazine protons at 2.50-2.62 ppm and the methine protons at 4.27 ppm.
In the 1H-spectrum in DMSO-d6 (Figure 2.4: Spectrum B), the amine proton peak at 8.51
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Figure 2.4: Proton NMR Spectra of PL343
Spectrum A: 1-d NMR spectrum in methanol-d4; Spectrum B: 1-d NMR spectrum in DMSO-d6
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ppm has a relative integration of only 1H. In the DMSO-d6 1H-spectrum, there is
additional splitting from the coupling between the amine proton peak at 8.51 ppm and the
adjacent methylene peak at 3.42 ppm.
Finally, in the NOESY spectrum acquired in DMSO-d6 (Figure 2.5) there are
through-space correlations from the methylene at 3.51 ppm (peak d) to the amine peak at
8.51 ppm and from the methylene peak at 3.51 ppm (peak d) to the pyridine peak at 6.98
ppm (peak b). These five features clearly indicate that PL343 is an analog with an
amine-linkage and, when contrasted with the PL74 spectral features, these observations
confirm that PL74 does not have the previously reported amine-linkage.

Figure 2.5: NOESY Spectrum of PL343 in DMSO-d6

(Right arrow indicates cross peak from amine proton peak to methylene peak d. Left arrow indicates
cross peak from aromatic peak b to methylene peak d.)
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Based on the evidence just presented, the molecule named PL74 has been
determined to have a pyridinium salt structure. The “yet-to-be-synthesized” aminelinkage structure will be named PL388 from here forward.
Once the structure of PL74 was determined to be a pyridinium salt, the spectra for
each analog I had synthesized were examined to determine which was a pyridinium salt.
It was found that every analog that was synthesized using a 4-aminopyridine starting
material resulted in a pyridinium salt; while each analog synthesized not using a 4aminopyridine had the expected amine linkage.
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Chapter 3

Structure Activity Relationship: Part 1

An SAR study was initiated for the purpose of optimizing in vitro antimalarial
activity and to gain insights into the mechanism of action of PL74. The quaternary
ammonium moiety is a unique feature among the compounds that have been made in the
Peyton laboratory to date. (See Figure 1.12 for examples of Peyton Lab Compounds)
The presence of a quaternary ammonium cation and its impact in the conjugated
aminopyridine system is therefore of special interest. Analogs with modifications to the
pyridine ring and the ethyl linker chain attached to the cationic center were prepared for
study and tested for in vitro antimalarial activity. In addition, analogs were prepared and
tested to investigate the role of RA-like moiety of this compound.
The general synthesis pathway (Figure 3.1) used for the pyridinium compounds
was the route reported by Steven Burgess.69 In this synthesis, chlorodiphenylmethane is
combined with 1-(2-hydroxyethyl)piperazine to give PL72. The alcohol is treated with
thionyl chloride, then treated with the appropriate 4-aminopyridine in ethanol to yield the
PL74 analog. This synthesis was found to be a simple and reliable method. However,
attempts to increase the yield of the final step by the addition of base gave the opposite
result; several bases were tried, and each attempt resulted in drastically diminished yield.
It was found that no base, including using only 1 eq of the amine (as opposed to the 4 eq
used by Burgess), led to improved yields for the addition of 4-aminopyridine.
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Figure 3.1: Synthesis Pathway for PL74 and Its Analogs
Another synthetic pathway was explored, as shown in Figure 3.2. In this
synthesis, the appropriate amine was treated with chloroacetyl chloride, resulting in an
acyl pyridinium. The isolated acyl pyridinium was then treated with
diphenylmethylpiperazine, followed by reduction with LiAlH4. The acyl pyridinium was
very easy to isolate but the yields were 20%, at best. The reduction in the final step was
very difficult and resulted in yields below 5%. Several of the analogs were made by this
route but it is not the recommended pathway because of the low yields.

Figure 3.2: Alternative Synthesis Pathway for PL74 Analogs
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The in vitro antimalarial activities of the purified products were measured through
drug susceptibility assays against P. falciparum parasites in red blood cell culture.63 The
results shown are measurements carried out in triplicate, and are interpreted as active or
inactive; compounds with an IC50 > 2500 nM are considered inactive. Repeat
measurements (in triplicate) were made only for PL74. The IC50 reported by Burgess was
IC50 of 185 nM against the CQ-sensitive P. falciparum D6 strain and 169 nM against the
CQ-resistant P. falciparum Dd2 strain. On a repeat test, PL74 had higher IC50 values of
385 nM against D6 (CQ-sensitive strain) and 245 nM against Dd2 (CQ-resistant strain).
This illustrates that there is some variability in the testing; thus smaller fluctuations in
IC50 (<3 fold) are only considered to be significant if a discernable trend across several
compounds was found and not considered significant if the fluctuation involved only a
single compound. Also, the higher, more recent results are the ones that will be used for
comparison since the IC50 measurements were made at or near the time of testing for the
other analogs.
A set of four compounds, PL324, PL325, PL327, and PL328, were made that
include substituents on the pyridine ring (Figure 3.3). The methyl and bromine
substituents were chosen because they are similar in size (van der Waal volumes of 22.7
Å3 and 23.9 Å3, respectively) and have the opposite electronic effects, methyl donating
and bromine withdrawing electron density. Analog PL327 was synthesized with a
bromine substituent at the ring position alpha to the quaternary ammonium nitrogen but
was converted to the methoxy during workup with 100% conversion.
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The Hammett sigma constant (σ) indicates the electronic effect of a substituent on
the acid dissociation of benzoic acid; these values can be used as an estimate in other
aromatic systems. Negative sigma values indicate that the substituent is donating
electrons into the system, and positive values indicate the withdrawal of electrons from
the system. The Hammett constant is dependent on the position on the
ring, relative to the carboxy moiety. In the meta-position, the substituent effect is
inductive; in the para-position, there is both an inductive and resonance effect. The
resonance effect can be estimated by the difference of the para- and meta-values.
Literature σmeta, σpara and the difference for the bromo, methyl, and methoxy substituents
are given in Table 3.1.

Table 3.1 The Hammett Substituent Constants
72
(σ) Based on Ionization of Benzoic Acid

The substituent effect in the orthoposition is more complicated in that it
includes a steric effect in addition to the
inductive and resonance effects, and σortho is

Substituent
Bromo
Methyl
Methoxy
Amino
Methylamino

σmeta
0.391
-0.069
0.115
-0.016
---

σpara
0.232
-0.107
-0.268
-0.66
-0.84

σpara-σmeta
-0.159
-0.038
-0.383
-0.64
---

generally not used. The closer the substituent is to the reaction center, the more enhanced
the effect will be; when the reaction center is in the ring, the substituent effect is
enhanced. The Hammett Equation cannot be rigorously applied to determine specific
effects in the complex pyridinium system. (It is also not accurate to apply the
nomenclature positions ortho, meta and para for the relationship to the quaternary
ammonium cation in the ring, however to simplify this discussion and stay in step with
the Hammett constants, ortho-to-the-cation and meta-to-the-cation will be used.) It can
be said that at the position meta-to-the-cation, the methyl will be electron donating and
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the bromo will be electron withdrawing. Also, it can be said that at the position ortho-tothe-cation it is not clear if the methyl and methoxy groups are electron donating or
withdrawing because of the steric contribution, but their effect may have a strong impact
on the reaction center because of their close proximity to the cation.
The analogs, PL324, PL325, PL327, and PL328, all show in vitro antimalarial
activity for both the CQ-sensitive and CQ-resistant strains; the IC50 values are shown in
Table 3.2. From these results it can be seen that substituents on the ring are generally
tolerated. With the addition of electron-donating methyl substituents on PL324 and
PL325 and the electron-withdrawing bromo substituent on PL328, there was little change

Figure 3.3: Analogs with Pyridine Ring Substituents

from the antimalarial activity of PL74.

Table 3.2: IC50 Values of Analogs with Pyridine
Ring Substituents (PL74 IC50 included for
comparison)

With the addition of a methoxy group on
PL327, there is a significant drop in

PL74
PL324
PL325
PL327
PL328

antimalarial activity .
The general tolerance for the
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IC50 (nM) D6
(CQ-Sensitive)
385
344
539
1529
433

IC50 (nM) Dd2
(CQ-Resistant)
245
229
378
836
300

addition of substituents to the pyridine ring suggests that at the site of action there is
space to accommodate the substituents as the compound performs its mechanism of
antimalarial action. This advantageous characteristic allows for future SAR
investigations and possibly increasing the functionality of this compound.
The methoxy substituent was not tolerated in the position ortho-to-the-cation,
while the methyl was tolerated. The electron contribution of the methoxy is unclear but it
certainly has a much larger capacity for electron donation through resonance than the
methyl substituent. If the steric constraints at this location allow for resonance, then it
may be that methoxy has a strong electron-donating effect and the resulting decreased
cationic charge is disfavored. However, if the steric constraints hinder resonance, then
the electron-withdrawing inductive effect of the oxygen in close proximity may be the
result of increased cationic charge being disfavored.
Analogs PL342, PL330, PL165 and PL240 show further examples of analogs that
may perturb the electronic nature of the quaternary aromatic nitrogen (Figure 3.4).
Analog PL342 has a methylamine substituent instead of a primary amine at a position
para-to-the-cation. The methylamine has a greater electron-donating ability than the
amine substituent, indicated by the larger negative sigma values (Table 3.1). A slight
increase in antimalarial activity is seen for PL342 in comparison to PL74, indicated by
the IC50 that is lower than the IC50 of PL74. The small increase is insignificant by the
evaluation standard set forth in this dissertation. However, the increase is still enough to
prompt the design of analogs that include stronger electron-donating substituents at this
location for future SAR studies.
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Figure 3.4: PL74 Analogs

The second aromatic nitrogen in

Table 3.3: IC50 Values for PL330, PL342,
PL240, and PL165 (PL74 IC50 included for
comparison)

PL330 serves as an electron sink by
inductive effects, strongly drawing electron
density away from the quaternary nitrogen.
The carbonyl group of PL165 also serves as
an even stronger electron-withdrawing

PL74
PL342
PL330
PL165
PL240

IC50 (nM) D6
(CQ-sensitive)
385
266
1880
>2500
647

IC50 (nM) Dd2
(CQ-resistant)
245
206
1385
>2500
984

influence on the quaternary ammonium. The more distant carbonyl in PL240 has only a
minor inductive effect on the quaternary ammonium. PL240, PL330 and PL165 all show
a drop in antimalarial activity; the magnitudes of the loss of activity increases with the
strength of electron-withdrawing modification (Table 3.3). Strong electron-withdrawing
effects reduce the antimalarial activity. The increase of the cationic charge seems to be
disfavored.
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In the analogs PL238, PL236, PL232 (Figure 3.5), the functionality of the RA-like
moiety is incrementally subtracted. This series was planned to help determine which
parts of the RA-like moiety are essential for antimalarial activity and/or reversal
activity for CQ-resistant strains. It was envisioned that a loss of antimalarial activity
against the resistant strain might be seen earlier in the series than the loss of activity
against sensitive strain. Instead, a most surprising result was seen: there is total loss of
antimalarial activity with the removal of even one phenyl ring (Table 3.4).

Figure 3.5: Analogs with RA Modifications
However, with the removal of a nitrogen
from the piperazine ring, the loss of a
phenyl ring is tolerated as shown by the
activity of PL297, possibly indicating
that it is the exposure of the nitrogen
that is the underlying cause for activity

Table 3.4: IC50 Values for PL238, PL236,
and PL232 (IC50 of PL74 included for
comparison)
IC50 (nM) D6
IC50 (nM) 7G8
(CQ-sensitive)
(CQ-resistant)
PL74
385
345(Dd2)
PL238
>2500
>2500
PL236
>2500
>2500
PL232
>2500
>2500
PL297
654
371(7G8)/ 684(Dd2)

loss.
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The sensitivity to RA modifications is a very different than what is seen for the
Reversed-CQ SAR. For quinoline analogs, PL06 and DM1020, the change from two
phenyl rings to one showed no loss of antimalarial activity.69 PL110, PL91 and PL228,
reveals a series of further RA modifications that led to significant increases in
antimalarial activity (see Figure 3.6).73 The intolerance for modification to the RA
moiety implies that the entirety of PL74 is the antimalarial pharmacophore. In this, PL74
analogs demonstrate a drastic departure from Reversed-CQ-like behavior, possibly
indicating a mode of action other than the inhibition of hemozoin.

Figure 3.6: Reversed-CQ Compounds with RA Modifications
(Compounds synthesized by Steven Burgess and Bornface Gunsaru with PL74 and PL238 included
for comparison)
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The inactivity of PL238, while differing from PL74 by the loss of a single phenyl,
suggests the possibility of an antimalarial different from the Reversed-CQs, and so
possibly an enzyme binding site. The regain of activity with the change to a piperidine
ring in PL297 may be showing the lipophilicity of a binding site. These indications of a
possible new mechanism of antimalarial activity warrants further investigation.
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Chapter 4

Structure Activity Relationship: Part 2

In the course of the SAR study, several analogs synthesized were made with the
pyridine ring attached to the head group via an amine linkage. It was surprising to find
that there is also antimalarial activity among these compounds. Eight compounds are
presented. Although the eight compounds comprise a sparse and somewhat disjointed
SAR study, they raise some interesting questions regarding the activity of the aminelinkage compounds.
The compounds were purified and the in vitro antimalarial activities were
measured in triplicate through drug susceptibility assays against P. falciparum parasites
in red blood cell culture.63 As before, the results are interpreted as active or inactive;
compounds with an IC50 > 2500 nM are considered inactive.
PL167 is the most active antimalarial compound among this group. PL167 is
based on the 3-aminopyridine and was synthesized via the alternate synthetic route for
the pyridinium salts; in this case the amine substituent acts as the nucleophile leading to
the amine linkage, instead of the aromatic nitrogen acting as the nucleophile leading to
the pyridinium salt as with 4-aminopyridine. The synthesis pathway is shown in Figure
4.1. PL169 was also made in this same reaction sequence but starting with the 2aminopyridine. The syntheses of the remaining analogs are quite varied and given in
Chapter 7.
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Figure 4.1: Synthesis Pathway for PL167

Upon in vitro testing, PL167 showed good antimalarial activity, with an IC50 of
450 nM against D6 (a CQ-sensitive strain) and 173 nM against Dd2 (a CQ-resistant
strain). While PL167, based on 3-aminopyridine, is an active compound, PL169, based
on the 2-aminopyridine, is inactive (Figure 4.2, Table 4.1). This is not the expected result
based on the quinoline compounds. In an SAR study of aminoquinolines, Egan found
that 2-aminoquinoline and 4-aminoquinoline derivatives which are conjugated had strong
antimalarial activity while the 3-aminoquinoline did not.54 Egan also found that the 4aminoquinoline derivatives had better antimalarial activity than the 2-aminoquinoline
derivatives.54 The strong antimalarial activity of PL169, the 3-aminopyridine derivative,
is uncharacteristic of the aminoquinoline antimalarial activity suggested by Egan.
PL360 is an analog of particular interest in that it was designed as a pyridine
mimic of CQ to address the question of whether or not these pyridine-based compounds
are recognized by the CQ resistance mechanism (Figure 4.2). It was hypothesized that if
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Figure 4.2: Amine-Linkage Analogs
Table 4.1: IC50 Values of Analogs of Analogs with
Amine Linkage (IC50 of PL74 included for comparison)

PL74
PL76
PL167
PL169
PL215
PL329
PL343
PL350
PL360
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IC50 (nM) D6
(CQ-Sensitive)

IC50 (nM) Dd2
(CQ-Resistant)

385
>2500
450
>2500
>2500
>2500
>2500
851
>2500

245
>2500
173
>2500
1267
>2500
1957
2030
>2500 (7G8)

this CQ mimic is active against the CQ-sensitive strain and not against the CQ-resistant
strain, then it may be concluded that the activity of the pyridine moiety is similar to the
quinoline moiety. Antimalarial testing resulted in an IC50 >2500 nM for both D6 (a CQsensitive strain) and 7G8 (a CQ-resistant strain). If there is CQ-like antimalarial activity
that arises from the 4-aminopyridine, it should be seen in this analog. The inactivity of
PL360 suggests that the aminopyridine moiety does not completely encompass the
antimalarial activity of the amine-linkage molecules; more than the aminopyridine seems
necessary for activity.
PL350, a 4-aminopyridine-based compound, is the closest analog to the aminelinkage structure first proposed for PL74 (and now referred to as PL388); PL350 differs
by the addition of a 3-hydroxy substituent (Figure 4.2). Upon in vitro testing PL350
showed antimalarial activity against the sensitive strain, with an IC50 of 851 nM against
D6 (a CQ-sensitive strain) and 2030 nM against Dd2 (a CQ-resistant strain), making
PL350 the only molecule in this study to show the significant reduction of reversal agent
activity with retention of antimalarial activity. A general trend that is seen among the
pyridine and quinoline compounds is that for a given compound the IC50 value is lower
against the CQ-resistant strain than against the CQ-sensitive strain. The trend can be
seen in the compounds in this study (Table 4.1). The trend may be a reflection of the
fitness level of the strains. The adaptations that endow a strain with drug resistance seem
to be costly in terms of overall fitness as shown by competitive growth measurements.66
With strain fitness in mind, the IC50 results for PL350 being 2.5 times higher against the
resistant strain than against the sensitive strain is a significant result. It is interesting that
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in this molecule the reversal agent activity seems to be uncoupled from the antimalarial
activity and yet no modifications have been made to what is perceived as the reversal
agent portion of the molecule. This may be an important design lead for investigation of
the essential moiety for the reversal of CQ resistance in further SAR studies of the aminelinkage compounds.
PL343 is arranged like PL350 but has a 3-nitro group instead of a 3-hydroxy
group; PL343 has an IC50 of >2500 nM for D6 (a CQ-sensitive strain) and 1957 nM for
Dd2 (a CQ-resistant strain). It is interesting that the change from the 3-hydroxy to the 3nitro substituent changes the CQ-sensitive antimalarial activity from 851 nM to inactive,
while the CQ-resistant antimalarial activity is the same for both (Table 4.2).
PL215 and PL329 have a carbon moiety inserted between the secondary amine
and the pyridine ring (Figure 4.2). For PL329, the carbon moiety is a carbonyl and the
compound is inactive against both strains. For PL215, the carbon moiety is a methyl
group and the compound is inactive against D6 (a CQ-sensitive strain) but retains slight
activity against Dd2 (a CQ-resistant strain). In addition, PL76 is based on a phenyl
moiety instead of a pyridine moiety and is found to be inactive for both the CQ-sensitive
and CQ-resistant strains, suggesting that the aromatic nitrogen is an essential moiety for
in vitro antimalarial activity. Certainly, a more thorough SAR study is needed to
elucidate the pattern of antimalarial activity among the amine-linkage molecules.
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Chapter 5

Quaternary Ammonium Compounds

Because the range among antimalarial drugs is limited in terms of number of
unique targets, and because cross-resistance to all deployed drugs continues to emerge, it
is urgent that new antimalarials continue to be developed with some priority given to
molecules that have modes of action different from those currently in use. If PL74 has a
unique mode of antimalarial action, as suggested in the SAR study, then it is important
that we explore this compound further to gain understanding of its antimalarial mode of
action and its suitability as a lead compound for drug development.
A survey of literature reveals rich veins of research into applications for
quaternary ammonium compounds. The work of Dr. Henri Vial and associates at
University of Montpellier II shows a relentless pursuit of understanding of the biogenesis
of phospholipids in P. falciparum and the rational design of novel choline inhibitors as
antimalarials (References included in discussion). A careful look at the work to elucidate
the mode of action of their lead compound gives insight into a possible mechanism of
activity and a possible direction for future work to optimize PL74 into a drug.

The Antimalarial Action of Albitiazolium
The P. falciparum blood stage proliferation process demands the biosynthesis of
large amounts of phospholipids for the construction of membranes. From the time of the
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parasite’s invasion of the red blood cell (RBC) until the rupture of the cell 48 hours later,
the phospholipid content of the cell increases 500-600 fold.74-76 Because the increased
amount of phospholipids is essential for the maturation and replication of the parasite, the
phospholipid synthesis process is an attractive target to consider for drug development.77
The biosynthesis of phospholipids in P. falciparum is well known.78-81 The
majority of the phospholipids are phosphatidylcholine (40-50%) and
phosphatidylethanolamine (35-45%).82 An overview of these synthetic pathways is
shown in Figure 5.1. The production of phosphatidylcholine begins with the uptake of
host choline into the infected RBC. The uptake occurs mainly via a saturatable process,
and occurs through the erythrocyte choline transporter. One quarter of the choline enters
via the New Permeation Pathway (NPP) which is a parasite-induced channel in the
membrane of the erythrocyte.83-87 The choline is further transported through the parasite
membranes through a dedicated choline transporter.88 The capacity of the transporters of
choline through the erythrocyte membrane is much lower than the capacity of the
transporters through the parasite membranes, making the trans-erythrocyte membrane
transport the probable rate-limiting step.88 Choline is transformed to phosphocholine in
the cytosol of the parasite, then to cytidine diphosphate choline, and finally to
phosphatidylcholine via choline kinase, CTP-phosphocholine cytidylyltransferase, and
choline/ethanolamine phosphotransferase.
Phosphatidylethanolamine is made from ethanolamine. Ethanolamine diffuses
from the plasma through both the erythrocyte and parasite membranes into the cytosol, or
is made by decarboxylation of serine.78-81 The serine is either imported or captured from
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hemoglobin degradation products. In the same manner as choline, ethanolamine is
transformed to phosphoethanolamine, then to cytidine diphosphate ethanolamine, and
finally to phosphatidylethanolamine via ethanolamine kinase, CTP-phosphoethanolamine
cytidylytransferanse, and choline/ethanolamine phosphotransferase. In addition,
phosphoethanolamine can be converted to phosphocholine by methylation via the
phosphoethanolamine methyltransferase. In the same way, phosphatidylethanolamine
can be converted to phosphotidylcholine (Figure 5.1).

Figure 5.1: Biosynthetic Pathways of Phospholipids
Remake of graphic from ChemMedChem 2012, 7, 22-31
Compartments: E: erythrocyte, CS: cytosome, PV: parasitophorous vacuole, DV: digestive vacuole
Transporters : NPP: new permeation pathway; OCT: organic-cation transporter; eChoT:erythtocyte
choline transporter
Enzymes: PfCK: choline kinase; PfCCT: CTP-phosphocholine cytidylyltransferase; PfCEPT:
choline/ethanolamine cytidylyltransferase; PfPMT: phosphoethanolamine methyltransferase; PLMT:
phospholipid methyltransferace; SD: serine decarboxylase
Substrates: Cho: choline; P-Cho: phosphocholine; CDP-Cho: cytidine diphosphate choline; PtdCho:
phosphatidylcholine; P-Etn: phosphoethanolamine; CDP-Etn: cytidine diphosphate ethanolamine;
PtdEtn: phosphatidylethanolamine; Hb: heme; Ser: serine; Etn: ethanolamine
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The pathways from choline to phosphatidylcholine (Figure 5.1: shown in black)
and from ethanolamine to phosphatidylethanolamine (Figure 5.1: shown in blue) are
known as the Kennedy pathways, and are highly conserved in eukaryotes. The pathway
from serine to phosphoethanolamine via decarboxylation and then to phosphocholamine
via methyltransferase has been identified in P. falciparum but is more plant-like in nature;
this pathway is named the serine decarboxylation-phosphoethanolamine methylation
(SDPM) pathway (Figure 5.1: shown in green).78-81
The Vial group set out to identify choline analogs with antimalarial activity. By
the screening of ammonium salts for antimalarial activity, several such analogs were
discovered. 89-91 By comparing and contrasting the active and inactive molecules, it was
seen that the antimalarial activity was increased by the addition of a 10-to-12 carbon
chain and by adding lipophilic bulk around the nitrogen, creating a head group between
200 and 400 Å3.91 A selection of a few of the more active compounds found from their
SAR studies are shown in Figure 5.2.

Figure 5.2: Choline Analogs
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The potential potencies of these compounds were revealed when bis-ammonium
salts were formed by tethering a set of duplicate ammonium compounds together with a
long carbon chain. From compounds shown in Figure 5.3, it can be seen that changing
the original mono-structure to a bis-structure can lead to a large improvement in
antimalarial activity, shown by the decrease in IC50 values.90
G25 and MS1 both showed good antimalarial activity in vitro as indicated by the
IC50 values shown.90,91 In addition, both G25 and MS1 showed potent activity in vivo
when administered intraperitoneally to P. vinckei-infected mice; their ED50 values were
0.22 mg/kg and 1.6 mg/kg, respectively. Further testing for compound G25 revealed its
potency against P. falciparum in Aotus monkeys; a complete cure was achieved at a dose
of 0.30 mg/kg. In spite of the good results seen for both of these bis-quaternary
compounds, they were found to have bioavailability problems on oral administration that
was attributed to the low permeability of the gastero-intestinal barrier to the permanent
cationic charges.90,91
T3 was chosen as the Vial group’s lead molecule because it was envisioned that a
neutral pro-drug could be designed that would improve the oral availability of the
drug.90,91 The neutral pro-drug (Pro-T3) is transformed to the drug by the enzymatic
action of an esterase.91 T3 and Pro-T3 have very good antimalarial activity in vitro
against P. falciparum; the IC50 of T3 is 2.25 nM and the IC50 of Pro-T3 is 3.0 nM.91 In
addition T3 showed good activity in vivo when administered intraperitoneally to P.
vinckei-infected mice with an EC50 of 0.2 mg/kg, however it was shown to be ineffective
when administered orally with an ED50 of 13 mg/kg.91 The in vivo activity of Pro-T3
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Figure 5.3: Mono- and Bis-Quaternary Ammonium Compounds
Table 5.1: The Antimalarial Activity of Mono- and Bis-Quaternary Ammonium Compounds
Mono-Compound
QA6
E26
MS23
T1

in vitro IC50 (nM)
500
420
1550
70

Bis-Compound
T4
G25
MS1
T3
Pro-T3
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in vitro IC50 (nM)
90
0.64
0.5
2.25
3.0

when administered intraperitoneally to P. vinckei-infected mice was nearly the same T3
with an IC50 of 0.25 mg/kg; Pro-T3 was found to be more effective than T3 when
administered orally with an EC50 of 5 mg/kg.91 The neutral pro-drug approach has been
successful as shown by activity upon oral administration. A Pro-T3 analog that could not
be transformed to the thiazolium showed an in vitro IC50 < 10 µM, suggesting the
transformation of Pro-T3 to the active form does occur in vivo.90
Based on the dramatic increase in the antimalarial activity seen in the bisammonium compounds, it was hypothesized based on the structures of the active analogs
that there are two active anionic binding sites on the target protein. The optimized chain
length suggests the distant between the active sites.91 The SAR included alterations to
the chain, and all alterations tried diminished the antimalarial activity. The negative
impact of polar functional groups added to the carbon chain suggested that the region
between the active sites is hydrophobic. The negative impact of aromatic rings that add
rigidity to the chain suggests that the pathway between the binding regions is narrow or
convoluted.91
In the paper, “Transport and Pharmacodynamics of Albitiazolium, an
Antimalarial Drug Candidate”, the Vial group reports the results of their exploration of
the mode of action of albitiazolium (T3). A detailed analysis of the inhibitory effect of
albitiazolium on phosphocholine and phosphoethanolamine biosynthesis was performed
for three distinct parasite development stages in the erythrocyte. The measurements were
made at the ring stage, which is the immature parasite stage from invasion to the
formation of the parasitophorous vacuole; the trophozoite stage, which is a maturation
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phase that includes heightened metabolism; and finally the schizont stage, in which the
DNA replicates and is followed by rapid cell division.92 Because the need for
phospholipids differs throughout the stages, it was expected that the potency of the drug
would show a stage-specific pattern. The drug concentration that inhibited 50% of the
phosphocholine synthesis (PC50) was determined to be 2.8 µM for the ring stage, 26 µM
for the trophozoite stage and 9.3 µM for the schizont stage.88 The drug concentration that
inhibited 50% of the phosphoethanolamine synthesis (PE50) was greater than 1000 µM
for all three developmental stages.88 Albitiazolium thus specifically inhibited
phosphocholine synthesis, and had its most potent immediate effect against the immature
parasite. In addition, increased choline concentrations in the cell media showed an
antagonistic effect on the antimalarial potency albitiazolium, indicating that not only does
albitiazolium inhibit phosphocholine synthesis, but it is that inhibition that leads to its
overall antimalarial affect. On further in vitro testing, it was shown that even with short
drug exposure times of 1 to 2 hours at any parasitic stage of development, the drug
accumulated within the intracellular parasite and led to its collapse at the onset of the
schizont stage.77,93
Albitiazolium was shown to accumulate selectively in the infected RBCs.93 When
erythrocytes were incubated at 37 oC in 30 µM albitiazolium media less than 0.01
pmol/107 RBC·min-1 entered the uninfected RBC. A 400-fold accumulation of drug
inside the infected RBC was measured when the cell media concentration was at 100
nM.88 The uptake of albitiazolium into the infected RBC proceeded linearly until
saturation at 5 µM.88 The selective uptake into the infected RBC implicates the parasite58

induced NPP. Furosemide is a known NPP inhibitor,84,94,95 and was shown to inhibit
albitiazolium uptake.88 However, even at very high concentrations furosemide was only
able to reduce the uptake by 85%.88 It appears that the majority of the albitiazolium
enters the RBC via the NPP, but some uptake is via an unknown route that is not
inhibited by furosemide.
Albitiazolium is then transported from the RBC into the parasite, most likely via
an organic cation transporter.89 The cross inhibition of choline on albitiazolium transport
and of albitiazolium on choline transport was taken as evidence that they leave the RBC
cytosol and enter the parasite by way of the same transporter.88 The capacity of NPPmediated transport of the albitiazolium from the plasma into the cytosol of the RBC is
much smaller than the capacity of its transport from the cytosol of the RBC into the
parasite.88 Because the second transporter in the series is larger, it seems reasonable to
conclude that the majority of the drug accumulation is inside the parasite, not in the
cytosol of the RBC. Accumulation measurements on a choline analog that is closely
related to albitiazolium was found to reside 77% inside the parasite and 23% in the
cytosol of the RBC.88
Albitiazolium interferes with choline phospholipid production in two ways,
inhibiting both the transport of choline from host plasma to parasite cytosol, and
inhibiting enzymatic transformations of choline to phosphatidylcholine. Albitiazolium
has been shown to inhibit the transport of choline with an IC50 of 19 µM in infected
RBCs incubated in the presence of 15 µM choline.88 When this was repeated in the
presence of furosemide, the NPP inhibitor, the IC50 for choline transport was 1.9 µM.88
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This suggests that the drug is inhibiting the transport of choline through the erythrocytic
choline transporter. The parasitic biosynthesis pathway from choline to
phosphatidylcholine involves three enzymes: choline kinase, CTP-phosphocholine
cytidylyltransferase, and choline/ethanolamine cytidylyltransferase. Albitiazolium
inhibited each of these enzymes with IC50s of 1.5 nM, 2.5 nM, and 4.2 nM, respectively,
when assessed on parasite extracts at optimal conditions for enzymatic catalysis.
In addition, it may also be that a portion of this drug accumulates in the digestive
vacuole of the parasite and inhibits the biocrystallization of hemozoin as has been
determined for other bis-thiazolium compounds.96 The affinity for the binding with heme
has been shown to both enhance the level of accumulation in the infected RBC and the
antimalarial activity of the bis-thiazolium compounds, although this has not been thought
to be the primary mode of action for this class of antimalarials.96

The Anticancer Activity of bis-Quaternary Ammonium Compounds
Neoplastic cancer is an area where bis-quaternary ammonium compounds are
found to be useful.97 Cancer is often viewed as simply wild proliferation of a cell but a
deeper look shows the basis of cancer is damage to genes that encode proteins used to
send signals to the nucleus to initiate cell growth, mitosis, differentiation, and/or
apoptosis.98 As a result of accentuated or diminished messages, cells begin to behave in
abnormal ways, often resulting in malignant tumors.
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The ras gene family encodes proteins that are involved in the signaling of cellular
functions. Oncogenic ras genes are found in 25% of human cancer and their mutations
have been found to have impaired ability to terminate signaling, resulting in the
upregulation of cell proliferation.99,100 Choline kinase (ChoK) is thought to be a part of
this signaling pathway that controls the regulation of cell growth.97 ChoK catalyzes the
transformation of choline phosphocholine (PCho) and elevated concentrations of PCho
are found in cancer cells that have ras mutations. Also, inhibition of ChoK with bisquaternary ammonium compounds has been shown to correlate with the inhibition of
tumor cell proliferation.97
Joaquin Campos, Antonio Espinosa, and coworkers have performed a QSAR
study based on the lead bis-quaternary ammonium compound of Hemicholinium-3
(Figure 4) in hope of developing an effective antiproliferant drug. Hemicholinium-3 is a
known, potent ChoK inhibitor in vitro, but it is unsuitable for use as a drug because it
causes respiratory paralysis.101 The SAR studies have led them to bis-aminopyridinium
compounds with improved activity without the respiratory paralysis side-effect.
Examples of their active compounds are shown in Figure 4.
Campos and Espinosa have found that the quaternary nitrogen is essential to
inhibitory activity and that an electron donating group at the position para-to-thequaternary-nitrogen on the pyridine ring enhances activity. They have also found that the
number and distribution of the cationic charges greatly influence their activity and
toxicity.
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Molecular orbital calculations were used in an attempt to find trends that
explained the changes in potency seen through the series.102 It was found that the ChoK
inhibition tightly correlated with the energies of the HOMOs and LUMOs of the
compounds; increases in the energy level of the frontier orbitals led to increased activity.
The HOMO and LUMO energies levels increased as the electron-donating ability of the
para substituent increased. The authors stressed the need for a quantitative approach to

Figure 5.4: Structure and Activity of Bis-Quaternary Compounds
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the SAR because analogs that appeared to be very different may in fact be electronically
similar, while those that appear similar may be very different. Also, it was pointed out
that a deeper understanding of the electronic nature of the inhibitor would lead to a better
understanding of the possible interaction between the enzyme and the inhibitor. In the
case of ChoK and the 4-aminopyridinium compounds it was rationalized that the high
energy level of the LUMO was probably more significant than the high energy level of
the HOMO. The high HOMO orbital is a trait that would be seen if the enzyme was
acting as a base, but it does not seem to apply to these compounds with an electrondeficient nitrogen as its active center. However, the higher energy of the LUMO may
suggest that the inhibitor is accepting electrons from the enzyme. Another possible
explanation is that the higher the energy of the LUMO results in a weaker solvent shell
around the molecule, easing the way to exclude water for a stronger interaction with the
enzyme.

Considerations for Future PL74 SAR
This author believes that it is quite possible that PL74 is acting as a choline
analog, thereby possibly inhibiting phospholipid synthesis in the P. falciparum parasite.
Dr. Vial’s research suggests that the mono-quaternary compounds inhibit the choline
transport from the plasma into the erythrocyte, so this would be the first possible site of
action to investigate for PL74. The diphenylmethylpiperazine headgroup on PL74 was in
fact added to the molecule for the purpose of inhibiting PfCRT (which is a transporter) so
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it may be that this moiety is also effective in the inhibition of the erythrocytic choline
transporter. From the results of the SAR presented in this dissertation, it can be seen that
the activity is dependent on the whole headgroup; the removal of a single phenyl ring was
not tolerated.
If PL74 is a choline synthesis inhibitor, it is a unique one. It is interesting that in
Dr. Vial’s study that they found that a 10-to-12 carbon chain was essential for strong
activity. PL74 does not have the “essential” long chain. Also, Dr. Vial suggests that the
optimum volume for the head group was about 200-400 Å3; If PL74 is considered a
chain-less headgroup, where the whole molecule is considered headgroup, then it is much
larger than the suggested dimensions. Also, there are some pyridinium compounds
among Dr. Vial’s analogs but no 4-aminopyridine compounds. In fact, in a search
conducted for analogous compounds in the literature, this author did not find any
antimalarial choline analogs that were 4-aminopyridiniums. If PL74 is acting as a
choline analog inhibiting phospholipid synthesis, then it would be novel in structure, and
this might indicate a new mode of action. The shape of the molecule, and the clues from
the SAR as an inverse map of an unknown active site, seem to indicate that it would bind
to an active site shaped differently than the site hypothesized by the Vial group based on
the shape of their active analogs.
Nevertheless, the large increase in activity for the bis-quaternary compounds
compared to the mono-compounds, makes this researcher wonder if PL74 is half of a
great antimalarial drug. Bis-PL74 analogs might lead to a fruitful class of molecules for
SAR exploration.
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The work of Campos and Espinosa is of interest because their analogs are 4aminopyridiniums applied to the inhibition of human phospholipid synthesis. The use of
molecular orbital modeling to look deeper into the trends seen, as the SAR of PL74 is
expanded, could be a beneficial addition. Also, the work they have done in finding
substituents that increase the electron donation of the amine would also be useful to
consider using in designing future PL74 analogs.
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Chapter 6

Summary and Conclusion

Malaria is an on-going tragedy, taking too many lives and locking people,
communities, and even nations into poverty and hopelessness. The goal to eradicate
malaria is certainly an honorable goal and hopefully achievable. To intervene and change
this situation, it will take everyone working together: Charitable people donating ITNs
for those who need them but cannot afford to buy them; scientists doing ingenious
science in pursuit of vaccines, producing the best vaccines possible; organizations
tracking resistance, making deployment policies, and evaluating the actions that are being
taken. But at the center of this campaign there has to be a continuous stream of safe,
affordable, curative drugs to save lives and decrease the opportunity for transmission of
the malaria parasites, staying at least one drug ahead of resistant strains.
The Peyton Lab Reversed-CQ project shows promise of being able to produce a
safe, inexpensive, effective antimalarial drug that can be of use in the effort to eradicate
malaria. By functionalizing CQ with an RA moiety the resistance mechanism can be
overcome, as demonstrated by the in vitro and in vivo activity of the prototype molecule,
PL01.
PL74 was first thought to be a minimal version of a Reversed-CQ compound and
an SAR study was pursued in hope that the activity could be optimized. During this
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work, it was discovered that the structure originally assumed for PL74 was incorrect and
that PL74 is a pyridinium salt.
In the SAR study there are two findings that indicate a different mode of action
for PL74. The intolerance of the removal of a phenyl group from the RA portion of the
molecule, revealed by the inactivity of analog PL238 in contrast with compounds made
by Steve Burgess and Bornface Gunsaru, showed a drastic departure from Reversed-CQ
behavior. The antimalarial activity of PL167, with 3-aminopyridine attached to the RA
group via an amine linkage, was unexpected; in addition, the inactivity of PL360, the
CQ-mimic, and PL169, with 2-aminopyridine attached to the RA group via an amine
linkage, was unexpected. These results are opposite the behavior predicted by earlier
aminoquinoline work reported by Egan. The overall message from this SAR is that PL74
is not like the Reversed-CQ compounds and the hope is that these indications are pointing
to not only a different, but a useful, antimalarial mechanism.
A review of the literature found that quaternary ammonium salts, including
pyridinium salts, are often biologically active molecules and often operate as choline
analogs. Two case studies were reviewed, one looking at Dr. Henri Vial’s work with
antimalarial choline analogs and the second looking at Campos/Espinosa’s work on
anticancer choline analogs. In both lines of research it was found that the bis-quaternary
drugs were significantly more active than the mono-compounds, and, in both cases, these
compounds exerted their cytotoxic action by inhibition in the phosphatidylcholine
biosynthesis pathway. The literature study uncovered a wealth of ideas and methods for
future investigations into the antimalarial action of PL74.
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Additional SAR study for PL74 is needed in two directions. The optimization of
the antimalarial activity of PL74 may be possible through the addition of electrondonating substituents both on the amine substituent and on the ring. Also, the design and
synthesis of bis-PL74 compounds seems to be an important next step for this research.
Using molecular orbital calculations in the design of analogs may bring more clarity to
the process. The exploration of the mode of action of PL74 should be continued because
of the great need for more antimalarial drugs and because there is a possibility that this
research could lead to an effective antimalarial drug.
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Chapter 7

Experimental Methods
All names were generated using ChemBioDraw Ultra 13.0. Purities were analyzed using
a Varian Prostar Binary HPLC system, measuring by UV detection at 254 and 325 nm,
using a Varian ProStar 325 UV/Vis dual wavelength detector using Method 2. Method 2
was done with Supelco Ascentis C18 column (15 cm x 4.6 cm, 5 µm pore size), from
99:5 water/acetonitrile with 0.1% formic acid in both to 30:70, at 1 mL/min, over 10
minutes. High resolution accurate mass data was generated by injecting
samples into methanol:water at a flow rate of 0.2ml/min directed to a Thermo LTQOrbitrap XL Discovery max spectrometer (San Jose, CA, USA) equipped with an ESI ion
max source. The ionization interface was operated in the positive mode using the
following settings: source voltage, 4 kV; sheath and aux gas flow rates, 20 and 5 units
respectively; tube lens voltage, 90 V; capillary voltage, 50 V; and capillary temperature,
300°C. The Orbitrap mass analyzer was externally calibrated prior to analysis to obtain
mass accuracy within ± 2-3 ppm. 1H, 13C and 2D NMR experiments were run on a
Bruker 600MHz AVANCE-III instrument, using the standard pulse sequences provided,
including zg30, zgpg30, cosygpqf, hsqcetgpsi2, hmbcgplpndqf, and noesyph, at 25°C.

PL72: 2-(4-Benzhydrylpiperazin-1-yl)ethan-1-ol
1-(2-Hydroxyethyl)piperazine (2.0 g, 15.4 mmol) was dissolved in DMF (20 mL).
K2CO3 (4.27 g, 3.1 mmol) and KI (catalytic amount) were added. The mixture was
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stirred at room temperature while chlorodiphenylmethane (2.74 mL, 3.12 g, 15.4 mmol)
was added dropwise. The solution was stirred at room temperature for two hours and
then heated to 76 oC for 22 hours. The reaction solution was cooled to room temperature,
diluted with distilled water (100 mL) and extracted with diethyl ether (3 x 20 mL). The
combined diethyl ether was washed with brine (30 mL), dried over MgSO4, and
evaporated to give PL72 (3.39 g, 11.4 mmol, 74%).

PL73: 1-Benyzhydryl-4-(2-chloroethyl)piperazine
PL72 (1.13 g, 3.8 mmol) was dissolved in chloroform (10 mL). DMF (2 drops) and
thionyl chloride (200 µL) was added and solution was refluxed with stirring for 1.5
hours. Additional thionyl chloride (400 µL) was added and the solution was refluxed for
40 more minutes, during which a white precipitate formed. The solid was collected by
filtration, washed with diethyl ether and air dried to give PL73 (~1.34 g, 3.8 mmol,
100%) and used without further purification.

Alternate Synthesis of PL73: Diphenylmethylpiperazine (25.21 g, 100 mmol) and K2CO3
(27.98 g, 202 mmol) was stirred in 1,2-dichloroethane (85.0 mL, 106 g, 1.1 mol) and
heated to 80oC for 48 hours. The reaction mixture was cooled to room temperature and
partitioned between water and CHCl3. The CHCl3 solution was evaporated down to
brown clay. The brown clay was separated on a silica column (40 g) with ethyl acetate
eluent to give PL73 (4.63g, 13.2 mmol, 13%).
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PL74: 4-Amino-1-[2-(4-benzhydrylpiperazin-1-yl)ethyl]pyridinium chloride
PL73 (1.34 g, 3.8 mmol) and 4-aminopyridine (0.53 g, 5.6 mmol) were stirred into EtOH
(15 mL) and refluxed for 21 hours. The reaction solution was condensed to half volume
by evaporation and the resulting white precipitate was collected by filtration, washed
with chilled EtOH and then with diethyl ether, and air dried to yield PL74 (0.49 g, 1.2
mmol, 32%) as a white solid. HPLC (Method 2) tR=5.72 min (99% pure). MS(ESI):
m/z=373.2385 (M+). 1H NMR δ (ppm)(600 MHz, CH3OH-d4): 8.03 (2 H, d, J = 7.22 Hz),
7.41-7.41 (4 H, m), 7.25 (4 H, t, J = 7.61 Hz), 7.16 (2 H, t, J = 7.36 Hz), 6.79 (2 H, d, J =
7.23 Hz), 4.15-4.20 (3 H, m), 2.74 (2 H, t, J = 5.79 Hz), 2.53 (4 H, s), 2.38 (3 H, br s).
13

C NMR δ (ppm)(600 MHz, CH3OH-d4): 160.8, 144.5, 144.1, 129.5, 129.0, 128.1,

110.3, 77.8, 58.8, 56.0, 54.3, 53.2.

PL76: [2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-phenylamine
PL73 (1.00 g, 3.4 mmol) and aniline (0.05 mL, 0.05 g, 0.54 mmol) was stirred together in
EtOH (3 ml) and microwave heated to 130 oC for 15 minutes. Two more additions of
aniline (each 0.1 mL, 0.1 g, 1.1 mmol) were added and the reaction was microwave
heated to 130 oC for 15 minutes after each addition. The solvent was evaporated and the
solid was purified on alumina with hexane/EtOAc gradient to 100% EtOAc, yielding
PL76 (0.03 g, 0.08 mmol, 3 %). HPLC (Method 2) tR=9.41 min (85% pure). MS(ESI):
m/z=372.4342 (M+).

13

C NMR δ (ppm)(CHCl3-d): 148.6, 142.8, 129.2, 128.5, 128.4,

127.9, 126.9, 126.9, 117.2, 112.9, 77.5, 76.3, 57.9, 56.7, 54.0, 53.2, 51.9, 51.8, 40.3, 1.0
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PL165: 4-Amino-1-[2-(4-benzhydryl-piperazin-1-yl)-acetyl]-pyridinium chloride
PL170 (0.66 g, 3.2 mmol) and diphenylmethylpiperazine (1.20 g, 4.8 mmol) were stirred
together in EtOH (3 mL) and microwave heated to 103 oC for 15 minutes. The solvent
was evaporated and the solid product was purified on a basic alumina column with a
EtOAc/MeOH gradient to 30% MeOH, yielding PL165 (0.51 g, 1.2 mmol, 38 %). HPLC
(Method 2) tR=7.31 min (92% pure). MS(ESI): m/z=387.2179 (M+). 1H NMR δ
(ppm)(600 MHz, CH3OH-d4): 8.41 (2 H, dd, J = 4.99, 1.63 Hz), 7.70 (2 H, dd, J = 5.01,
1.65 Hz), 7.47 (4 H, d, J = 7.73 Hz), 7.29 (4 H, t, J = 7.60 Hz), 7.19 (2 H, t, J = 7.37 Hz),
4.30 (1 H, s), 3.25 (2 H, s), 2.67 (4 H, s), 2.53 (4 H, br s).

13

C NMR δ (ppm)(CH3OH-d4):

13

C NMR δ (ppm)(CH3OH-d4): 171.8, 150.9, 147.5, 144.1, 129.6, 129.0, 128.1, 115.2,

77.7, 62.9, 54.6, 52.9.

PL166: 2-(4-Benzhydrylpiperazin-1-yl)-N-pyridin-3-yl-acetamide
PL171 (1.71 g, 10.0 mmol), Diphenylmethylpiperazine (2.88 g, 11.4 mmol), K2CO3 (2.11
g, 15.2 mmol), and KI (1.80 g, 10.8 mmol) were stirred in DMF (60 mL) and refluxed for
24 hours at 60 oC. The reaction mixture was cooled, diluted with water and extracted
with DCM. The DCM was evaporated and the resulting dark oil was purified on an
alumina column with EtOAc eluent, yielding PL166 (2.33 g, 6.0 mmol, 60%).

PL167: [2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-pyridin-3-yl-amine
PL166 (2.5 g, 6.5 mmol) was dissolved in DCM (30 mL) and chilled to 0 oC. Then 1 M
LiAlH in THF(3 mL) was added dropwise. The solution was stirred at 0 oC for one hour
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and then at room temperature for 18 hours. The reaction was followed by TLC. The
solution was again chilled to 0 oC, then 1 M LiAlH4 in THF (2 mL) 2 was added and the
mixture was stirred for 1 hour at 0 oC and then at room temperature for 48 hours. The
reaction was diluted with water and extracted with EtOAc, yielding PL167, (trace
amount). HPLC (Method 2) tR=6.24 min (96% pure). MS(ESI): m/z=373.2385 (M+). 1H
NMR δ (ppm)(600 MHz, CH3OH-d4): 7.81 (1 H, d, J = 2.86 Hz), 7.64 (1 H, dd, J = 4.71,
1.33 Hz), 7.31-7.35 (4 H, m), 7.16 (4 H, t, J = 7.61 Hz), 7.03-7.09 (3 H, m), 6.92 (1 H,
ddd, J = 8.38, 2.88, 1.34 Hz), 4.14 (1 H, s), 3.14 (2 H, s), 2.52 (2H, t, J = 6.77 Hz), 2.47
(4 H, br s), 2.36 (4 H, br s).

13

C NMR δ (ppm)(600 MHz, CH3OH-d4): 146.9, 144.1,

137.7, 135.7, 129.6, 129.0, 128.1, 125.5, 120.1, 77.8, 58.0, 54.5, 52.8, 41.0.

PL168: 2-(4-Benzhydrylpiperazin-1-yl)-N-pyridin-2-yl-acetamide
PL172 (1.72 g, 6.5 mmol), diphenylmethylpiperazine (2.87 g, 11.4 mmol), K2CO3 (2.12
g, 15.4 mmol), and KI (1.75 g, 12 mmol) were stirred in DMF (50 mL) and refluxed for
24 hours at 60 oC. The reaction mixture was cooled, diluted with water and extracted
with DCM. The DCM was evaporated and the resulting thick oil was purified on an
alumina column with 50%EtOAc/50% hexane eluent, yielding PL168 (1.73 g, 4.48
mmol, 69%).

PL169: [2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-pyridin-2-yl-amine
PL 168 (0.67 g, 1.7 mmol) was dissolved in THF (12 mL) and added dropwise into a 1 M
LiAlH4 in THF solution (3.6 mL) which was chilled to 0 oC. The reaction was stirred on
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ice for 15 minutes, then stirred at room temperature for 18 hours. The reaction was
quenched with the addition of EtOAc (5 mL), then water (10 mL), then 2 M NaOH (1
mL). The reaction solution was diluted with water (30 mL) and extracted with EtOAc and
purified on Alumina with EtOAc, yielding PL169 (0.60 g, 1.6 mmol, 95%). HPLC
(Method 2) tR=6.68 min (76% pure). MS(ESI): m/z=373.2386 (M+). 1H NMR δ
(ppm)(600 MHz, CH3OH-d4): 7.92-7.93 (1 H, m), 7.46 (5 H, d, J = 7.75 Hz), 7.29 (4 H, t,
J = 7.62 Hz), 7.19 (2 H, t, J = 7.37 Hz), 6.54-6.55 (2 H, m), 4.27 (1 H, s), 3.42 (2 H, t, J =
6.62 Hz), 2.65 (3 H, s), 2.54-2.54 (8 H, br m).

13

C NMR δ (ppm)(600 MHz, CH3OH-d4):

13

C NMR δ (ppm)(CH3OH-d4): 148.0, 144.1, 138.9, 129.6, 129.5, 129.0, 128.1, 113.4,

78.1, 77.8, 58.3, 54.4, 52.8, 39.5.

PL170: 4-Amino-1-(2-chloroacetyl)pyridinium chloride
4-Aminopyridine (2.65 g, 28.0 mmol) and K2CO3 (5.80 g, 41.7 mmol) was dissolved in
DCM (75 mL). Chloroacetylchloride (3.5 ml) was added dropwise and the solution was
stirred and refluxed for 4 hours. The reaction solution was diluted with 200 mL of ice
water and the resulting precipitate was filtered and air dried, yielding PL170 (1.00 g, 4.8
mmol, 17%). PL170 was used without further purification.

PL171: 2-Chloro-N-pyridin-3-ylacetamide
3-Aminopyridine (2.83 g, 30.1 mmol) was dissolved in DCM (100 mL).
Chloroacetylchloride (3.5 ml) was added dropwise and the solution was stirred at room
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temperature for three days. The solid was filtered, washed with DCM and air dried,
yielding PL 171 (5.98 g, 34.8 mmol, 86%), which was used without further purification.

PL172: 2-Chloro-N-pyridin-2-ylacetamide
2-Aminopyridine (2.84 g, 30.2 mmol) was dissolved in DCM (100 mL).
Chloroacetylchloride (3.5 ml) was added dropwise and the solution was stirred at room
temperature for three days. The solid was filtered, washed with DCM and air dried,
yielding PL 172 (4.41 g, 25.7 mmol, 85%), which was used without further purification.

PL215: [2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-pyridin-4-ylmethylamine
PL373 (3.37 g, 11.4 mmol) and 4-pyridine carboxaldehyde (2.5 mL, 2.2 g, 14.7 mmol)
were stirred together with MgSO4 in toluene at room temperature for 48 hours. The
solution was filtered and then the solvent evaporated. The solid was taken up in MeOH .
NaBH4 (0.88 g) was added and the solution was stirred for 4 days. The reaction was
quenched with water, the product was extracted CHCl3 and then the solvent was
evaporated. The solid was purified on a basic alumina column with a 20%MeOH/80%
EtOAc eluent, yielding PL215 (1.14 g, 2.95 mmol, 26 %). HPLC (Method 2) tR=4.67
min (87% pure). MS(ESI): m/z=387.2544 (M+). 1H NMR δ (ppm)(600 MHz, CH3OHd4): 1H NMR δ (ppm)(CH3OH-d4): 8.46 (2 H, d, J = 5.29 Hz), 7.41 (6 H, t, J = 7.56 Hz),
7.26 (4 H, t, J = 7.55 Hz), 7.17 (2 H, d, J = 7.42 Hz), 4.22 (1 H, s), 3.82 (2 H, s), 2.70 (2
H, t, J = 6.72 Hz), 2.53 (3 H, t, J = 6.94 Hz). 13C NMR δ (ppm)(CH3OH-d4): 150.2,
144.0, 129.6, 129.0, 128.1, 125.0, 125.0, 77.7, 58.2, 54.5, 53.0, 52.7, 46.2.
75

PL232: 4-Amino-1-ethyl-pyridinium chloride
4-Aminopyridine (1.0 g, 10.6 mmol) and acetylchloride (7.6 mL, 6.9 g, 88 mmol) were
dissolved into DCM and stirred at room temperature for 12 hours. The reaction mixture
was filtered and the solids were washed with DCM and then purified on a silica column
with an eluent mix of 90% CHCl3/10% MeOH. The resulting solid was dissolved in THF
(8 mL) and added dropwise to a chilled solution of 1 M LiAlH4 in THF (3 mL) which had
been chilled to 0 oC. The reaction was stirred for 1 hour at 0 oC and then for 24 hours at
room temperature. The reaction was quenched with water, the solvent was evaporated,
and the residue was purified on silica column with an eluent mix of 90% CHCl3/10%
MeOH, yielding PL232 (0.06 g, 0.38 mmol, 3.6%). HPLC (Method 2) tR=1.49 min (85%
pure). MS(ESI): m/z=123.09128 (M+). 1H NMR δ (ppm)(600 MHz, CH3OH-d4): 7.98 (2
H, d, J = 5.77 Hz), 6.54 (2 H, dd, J = 5.32, 1.61 Hz), 3.20 (2 H, q, J = 7.22 Hz), 1.26 (3 H,
t, J = 7.22 Hz).

PL236: 4-Amino-1-[2-(4-methyl-piperazin-1-yl)-ethyl]-pyridinium chloride
4-Aminopyridine (1.05 g, 11.2 mmol), 1,2-dichloroethane (8.0 mL, 6.4 g, 64 mmol) and
Et3N (0.5 mL, 0.7 g, 6.8 mmol) were stirred together and microwave heated to 120 oC for
15 minutes. The reaction was cooled to 0 oC and filtered. The filtrate was evaporated, and
the residue was stirred in to 1-methylpiperazine (6.0 ml, 6.6g, 67 mmol) and heated to 95
o

C for 26 hours. The reaction mixture was cooled, diluted with MeOH and filtered. The

filtrate was evaporated and the residue was purified on a basic alumina column with a
EtOAc/MeOH gradient to 20% MeOH, yielding PL236 (0.13g, 0.51 mmol, 4.5%).
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HPLC (Method 2) tR=1.19 min (100% pure). MS(ESI): m/z=221.17657 (M+). 1H NMR δ
(ppm)(600 MHz, CH3OH-d4): 8.08 (2 H, m), 6.84 (2 H, m), 4.23 (2 H, t, J = 5.74 Hz),
2.78 (2 H, t, J = 5.75 Hz), 2.51-2.54 (8 H, br m), 2.29 (3 H, s). 13C NMR δ (ppm)(600
MHz, CH3OH-d4): 13C NMR δ (ppm)(CH3OH-d4): 161.6, 145.3, 111.2, 59.5, 56.8, 54.3,
46.8.

PL238: 4-Amino-1-[2-(4-benzyl-piperazin-1-yl)-ethyl]-pyridinium chloride
PL364 (0.58 g, 1.7 mmol) was dissolved in anhydrous THF (30 mL) and chilled to 0 oC.
1M LiAlH4 in THF (2.8 ml, 2.8 mmol LiAlH4) was added dropwise with stirring for 1
hour and then at room temperature for 12 hours. More 1 M LiAlH4 in THF (4.0 ml, 4.0
mmol LiAlH4) was added and the reaction was stirred at 60 oC for 12 hours. The reaction
was quenched with EtOAc (10 mL) , and then water (30 mL). The product was extracted
from the quenched reaction with EtOAc (6x, 300 mL total). The EtOAc was evaporated
and the resulting residue was purified on a basic alumina column with EtOAc/MeOH
gradient to 40% MeOH, yielding PL238, (0.29 g, 0.87 mmol, 51%). HPLC (Method 2)
tR=1.50 min (89% pure). MS(ESI): m/z=297.20771 (M+). 1H NMR δ (ppm)(600 MHz,
CH3OH-d4): 1H NMR δ (ppm)(CH3OH-d4): 8.00 (2 H, d, J = 5.83 Hz), 7.34-7.36 (4 H,
m), 7.27-7.31 (1 H, m), 6.58 (2 H, dd, J = 5.35, 1.64 Hz), 3.57 (2 H, s), 3.31 (2 H, t, J =
6.75 Hz), 2.63 (2 H, t, J = 6.76 Hz), 2.56-2.58 (8 H, br m).

13

C NMR δ (ppm)(600 MHz,

CH3OH-d4): 13C NMR δ (ppm)(CH3OH-d4): 158.3, 146.3, 144.1, 143.3, 129.6, 129.0,
128.1, 110.0, 104.8, 77.8, 58.6, 56.3, 54.2, 53.3.
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PL240: 4-amino-1-[2-(4-benzhydryl-piperazin-1-yl)-2-oxo-ethyl]-pyridinium
chloride
Diphenylmethylpiperazine (2.52 g, 10.0 mmol) and K2CO3 (2.83 g, 20.0 mmol) were
slurried in DCM (50 mL). Chloroacetyl chloride (2.4 mL, 3.4 g, 30 mmol) was added
slowly and stirred at room temp for 12 hours. The reaction mixture was partitioned
between DCM and water. The DCM solution was dried over MgSO4 and then the solvent
was evaporated to yield a thick oil. The oil and 4-aminopyridine (0.94 g, 10 mmol) were
stirred in EtOH (100 mL) and heated to 90 oC for 12 hours. The solvent was evaporated
and the resulting oil was purified on basic alumina with an ethylactetate/methanol
gradient to 40% methanol to yield PL240 (3.04 g, 7.2 mmol, 72%). HPLC (Method 2)
tR=7.74 min (97% pure). MS(ESI): m/z=387.21776 (M+). 1H NMR δ (ppm)(600 MHz,
CH3OH-d4): 7.92-7.94 (2 H, m), 7.49-7.49 (5 H, m), 7.32 (5 H, t, J = 7.62 Hz), 7.23 (2 H,
t, J = 7.38 Hz), 6.82-6.87 (2 H, m), 5.19 (2 H, s), 4.36 (1 H, s), 3.64 (2 H, t, J = 4.94 Hz),
3.57 (2 H, t, J = 4.91 Hz), 2.54 (2 H, t, J = 4.85 Hz), 2.45 (2 H, t, J = 5.00 Hz).
δ (ppm)(CH3OH-d4):

13

C NMR

13

C NMR δ (ppm)(CH3OH-d4): 166.0, 161.1, 145.4, 143.6, 129.7,

129.0, 128.3, 110.3, 77.2, 52.8, 52.5, 49.6, 46.0, 43.7.

PL297: 4-Amino-1-[2-(4-benzyl-piperidin-1-yl)-ethyl]-pyridinium
PL170 (0.65 g, 3.1 mmol) and 4-benzylpiperidine (0.58 mL, 0.58 g, 5.7 mmol) and
K2CO3 (1.14 g, 8.2 mmol) were stirred together in DMF and room temperature for 2
weeks. The solution was filtered and evaporated, resulting in an oily residue. The
residue was dissolved in THF (25 mL) and 1 M LiAlH4 in THF (0.6 mL was added; the
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solution was stirred at room temperature for 12 hours. The reaction was quenched with
EtOAc , then with water, and then cooled to room temperature. The product was
extracted with EtOAc (4x, 300 mL total). The solvent was evaporated and the resulting
oil was purified on a silica column with 30% MeOH/70% EtOAc, yielding PL297 (0.13
g, 0.39 mmol, 13 %). HPLC (Method 2) tR=1.5 min (55% pure). MS(ESI): m/z=xxx
(M+).

PL324: 4-Amino-1-[2-(4-benzhydrylpiperazin-1-yl)-ethyl]-2-methylpyridinium
chloride
PL73 (1.57 g, 5.0 mmol) and 4-amino-2-methylpyridine (0.54 g, 5.0 mmol) were stirred
into EtOH (10 mL) and microwave heated to 100 oC for 15 minutes. The solvent was
evaporated and the residue was columned on a basic alumina column with an
ethylacetate/methanol gradient to 20% methanol, to yield PL324 (0.83 g, 2.0 mmol, 40%
yield). HPLC (Method 2) tR=5.65 min (98% pure). MS(ESI): m/z=387.2544 (M+). 1H
NMR (ppm)(600 MHz, CH3OH-d4): 7.96 (1 H, d, J = 6.93 Hz), 7.41 (4 H, d, J = 7.68
Hz), 7.25 (4 H, t, J = 7.61 Hz), 7.17 (2 H, d, J = 7.39 Hz), 6.67-6.71 (2 H, m), 4.18-4.20
(3 H, m), 2.72 (2 H, t, J = 5.95 Hz), 2.30-2.61 (11 H, m).
13

13

C NMR δ (ppm)(CH3OH-d4):

C NMR δ (ppm)(CH3OH-d4): 160.8, 153.7, 145.8, 144.1, 129.6, 129.0, 128.1, 111.3,

109.2, 77.8, 58.4, 54.6, 53.2, 52.5, 19.9.
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PL325: 4-Amino-1-[2-(4-benzhydrylpiperazin-1-yl)-ethyl]-3-methylpyridinium
chloride
PL73 (1.56 g, 5.0 mmol) and 4-amino-3-methylpyridine (0.54 g, 5.0 mmol) were stirred
together in EtOH (10 ml) and microwave heated to 100 oC for 15 minutes. The solvent
was evaporated and the residue was columned on a basic alumina column with an
ethylacetate/methanol gradient to 30% methanol, to yield PL325 (1.48 g, 3.5 mmol, 70%
yield). HPLC (Method 2) tR=5.86 min (99% pure). MS(ESI): m/z=287.2543 (M+). 1H
NMR (ppm)(600 MHz, CH3OH-d4): 7.97-7.98 (2 H, m), 7.41 (4 H, d, J = 7.69 Hz), 7.25
(4 H, t, J = 7.55 Hz), 7.17 (2 H, d, J = 7.40 Hz), 6.80 (1 H, d, J = 7.03 Hz), 4.17-4.18 (3
H, m), 2.74 (2 H, t, J = 5.85 Hz), 2.53 (4 H, s), 2.38 (3 H, br s), 2.16 (3 H, s).

13

C NMR δ

(ppm)(CH3OH-d4): 144.1, 143.0, 142.7, 129.6, 129.0, 128.1, 109.5, 77.7, 58.8, 56.0, 54.3,
53.2, 14.4.

PL327: 4-Amino-1-[2-(4-benzhydrylpiperazin-1-yl)-ethyl]-2-methoxypyridinium
chloride
PL73 (0.96 g, 3.1 mmol) and 4-amino-2-bromopyridine (0.52 g, 3.0 mmol) were stirred
together in EtOH (3 mL) and microwave heated to 100 oC for 10 minutes. The solvent
was evaporated and the residue was columned on a basic alumina column with an
ethylactate/methanol gradient to 30% ethanol to yield PL327 (mass not recorded). HPLC
(Method 2) tR=5.85 min (96% pure). MS(ESI): m/z=403.2492 (M+). 1H NMR (ppm)(600
MHz, CH3OH-d4): 1H NMR δ (ppm)(CH3OH-d4): 7.75 (1 H, d, J = 7.34 Hz), 7.41-7.41 (4
H, m), 7.25 (4 H, t, J = 7.61 Hz), 7.17 (2 H, d, J = 7.37 Hz), 6.49 (1 H, dd, J = 7.33, 2.34
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Hz), 6.28 (1 H, d, J = 2.34 Hz), 4.20 (1 H, s), 4.15 (2 H, t, J = 6.13 Hz), 4.05 (3 H, s),
2.67 (2 H, t, J = 6.14 Hz), 2.54 (5 H, s), 2.38 (3 H, br s).

13

C NMR δ (ppm) (600 MHz,

CH3OH-d4): 13C NMR δ (ppm)(CH3OH-d4): 201.5, 163.3, 161.3, 144.1, 143.4, 129.6,
129.0, 128.1, 105.7, 89.7, 77.8, 58.5, 57.7, 54.4, 53.1.

PL328: 4-Amino-1-[2-(4-benzhydryl-piperazin-1-yl)-ethyl]-3-bromo-pyridinium
chloride
PL73 (1.05 g, 3.3 mmol) and 4-amino-3-bromopyridine (0.51 g, 3.0 mmol) were stirred
together in EtOH (3 mL) and microwave heated to 100 oC for 10 minutes. The solvent
was evaporated and the residue was columned on a basic alumina column with an
ethylactate/methanol gradient to 30% ethanol to yield PL328 (0.85g, 1.7 mmol, 52%).
HPLC (Method 2) tR=5.82 min (97% pure). MS(ESI): m/z=451.1497 (M+). 1H NMR
(ppm) (600 MHz, CH3OH-d4): 1H NMR δ (ppm)(CH3OH-d4): 8.57 (1 H, d, J = 1.70 Hz),
8.09 (1 H, dd, J = 7.16, 1.73 Hz), 7.39-7.43 (4 H, m), 7.26 (4 H, t, J = 7.61 Hz), 7.16 (2
H, t, J = 7.36 Hz), 6.94 (1 H, d, J = 7.14 Hz), 4.21-4.22 (3 H, m), 2.75 (2 H, t, J = 5.67
Hz), 2.54 (5 H, s), 2.38 (3 H, br s).

13

C NMR δ (ppm) (600 MHz, CH3OH-d4): 13C NMR

δ (ppm)(CH3OH-d4): 158.3, 146.3, 144.1, 143.3, 129.6, 129.0, 128.1, 110.0, 104.8, 77.8,
58.6, 56.3, 54.2, 53.3.

PL 329: N-[2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-isonicotinamide
PL73 (4.17 g, 13.2 mmol) and Huing’s base (5 mL) were dissolved in CHCl3 (150 mL).
Nicotinoyl chloride (3.0 g, 17 mmol) was added in small portions and the reaction was
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stirred for five days. The solution was filtered, washed with saturated NaHCO3 solution
(1x), washed with water (4x), and then the solvent was evaporated. The solid was
purified on Alumina column with EtOAC/MeOH gradient to 30% MeOH, yielding
PL329 (0.67 g, 1.7 mmol, 13 %). HPLC (Method 2) tR=7.73 min (92% pure). MS(ESI):
m/z=401.2338 (M+). 1H NMR δ (ppm)(600 MHz, CH3OH-d4): 8.68 (2 H, dd, J = 4.68,
1.61 Hz), 7.76 (2 H, dd, J = 4.60, 1.65 Hz), 7.42 (4 H, d, J = 7.68 Hz), 7.26 (4 H, t, J =
7.61 Hz), 7.16 (2 H, t, J = 7.37 Hz), 4.24 (1 H, s), 3.54 (2 H, t, J = 6.76 Hz), 2.42-2.75
(10 H, br m).

PL330: 1-[2-(4-Benzhydrylpiperazin-1-yl)-ethyl]pyrimidin-4-ylamine
PL73 (1.05 g, 3.3 mmol) and 3-aminopyrimidine were stirred together in ethanol (5 mL)
and microwave heated at 100 oC for 15 minutes. The solid was filtered, then air dried,
then columned on a basic alumina column with EtOAc/MeOH gradient up to 40%
MeOH, and followed by recrystallization in MeOH, yielding PL330 (.69 g, 1.6 mmol,
51%). HPLC (Method 2) tR=5.32 min (99% pure). MS(ESI): m/z=374.2339 (M+). 1H
NMR δ (ppm)(CH3OH-d4): 8.57 (1 H, d, J = 1.88 Hz), 8.14 (1 H, dd, J = 7.45, 2.02 Hz),
7.41 (4 H, d, J = 7.63 Hz), 7.26 (4 H, t, J = 7.56 Hz), 7.17 (2 H, d, J = 7.32 Hz), 6.74 (1
H, d, J = 7.45 Hz), 4.20 (1 H, s), 4.17 (2 H, t, J = 5.55 Hz), 2.74 (2 H, t, J = 5.56 Hz),
2.55 (4 H, s), 2.38 (2 H, s).

13

C NMR δ (ppm)(600 MHz, CH3OH-d4): 13C NMR δ

(ppm)(CH3OH-d4): 13C NMR δ (ppm)(CH3OH-d4): 165.9, 155.2, 147.2, 144.1, 129.6,
129.0, 128.1, 106.0, 77.8, 58.2, 54.2, 53.2, 53.1.

82

PL342: 1-[2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-4-methylamino-pyridinium
chloride
PL73 (0.89 g, 2.8 mmol) and 4-(methylamino)pyridine (0.30 g, 2.8 mmol) were stirred in
EtOH (3 mL), then microwave heated to 130 oC for 15 minutes. The solvent was
evaporated and the residue was purified on a basic alumina column with EtOAc/MeOH
gradient to 40% MeOH, yielding PL 342 (0.1 g, 0.24 mmol, 8.8%). HPLC (Method 2)
tR=5.80 min (99% pure). MS(ESI): m/z=387.2543 (M+). 1H NMR δ (ppm)(600 MHz,
CH3OH-d4): 1H NMR δ (ppm)(CH3OH-d4): 8.13-8.14 (1 H, m), 7.97 (1 H, dd, J = 7.16,
1.86 Hz), 7.41-7.41 (4 H, m), 7.25 (4 H, t, J = 7.61 Hz), 7.16 (2 H, t, J = 7.36 Hz), 6.806.81 (2 H, m), 4.19 (3 H, t, J = 5.82 Hz), 2.97 (3 H, s), 2.74 (2 H, t, J = 5.79 Hz), 2.53 (4
H, s), 2.38 (4 H, br s).

13C

NMR δ (ppm)(600 MHz, CH3OH-d4): 159.5, 145.3, 144.1,

142.8, 129.6, 129.0, 128.1, 111.4, 105.8, 77.8, 58.8, 55.9, 54.3, 53.2.

PL343: [2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-(3-nitro-pyridin-4-yl)-amine
PL373 (1.05 g, 3.6 mmol) and 4-chloro-3-nitropyridine were slurried in water (4 mL) and
microwave heated to 130 oC for 30 minutes. The reaction mixture was diluted with
additional water (100 mL) and extracted with EtOAc (3x; 300 mL total). The EtOAc was
evaporated and the residue was columned on basic alumina with EtOAc/MeOH gradient
to 30% MeOH, yielding PL343 (0.69g, 1.7 mmol, 46 %). HPLC (Method 2) tR=6.87 min
(98% pure). MS(ESI): m/z=418.2241 (M+). 1H NMR δ (ppm)(600 MHz, CH3OH-d4):
9.08 (1 H, s), 8.22 (1 H, d, J = 6.31 Hz), 7.46-7.48 (5 H, m), 7.29 (5 H, t, J = 7.62 Hz),
7.19 (2 H, t, J = 7.36 Hz), 6.98 (1 H, d, J = 6.33 Hz), 4.27 (1 H, s), 3.51 (2 H, t, J = 6.34
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Hz), 2.74 (2 H, t, J = 6.33 Hz), 2.62 (4 H, br s), 2.50 (4 H, br s).

13

C NMR δ

(ppm)(CH3OH-d4): 13C NMR δ (ppm)(CH3OH-d4): 152.9, 150.1, 149.1, 144.2, 131.2,
129.6, 129.0, 128.1, 110.1, 77.9, 56.4, 54.1, 53.2, 40.2.

PL350: 4-[2-(4-Benzhydryl-piperazin-1-yl)-ethylamino]-pyridin-3-ol
PL343 (0.22 g, 0.53 mmol) was dissolved in MeOH and evaporated onto neutral
Alumina. FeCl3 (0.23 g, 1.4 mmol) and hydrazine monohydrate (2.5 mL, 2.4 g, 48.5
mmol ) was ground into the alumina. The alumina was loaded into a microwave vial and
heated at 130% for 10 minutes. The mixture was cooled, slurried in EtOAc and filtered
through Celite. The EtOAc was evaporated down to a thick oil. The oil was brought up
in dry THF and added dropwise into a boiling solution of dry THF (10 mL) with isoamyl
nitrite (0.1 mL). The solution was stirred and refluxed for 4 hours, then evaporated down
to oil and purified on an alumina column with EtOAc/MeOH gradient, yielding the
hydroxide side product (mass not recorded ). HPLC (Method 2) tR=7.59 min (92% pure).
MS(ESI): m/z=388.29800 (M+).

PL360: 1N,1N-Diethyl-4N-pyridin-4-ylpentane-1,4-diamine
4-Chloropyridine (2.05 g, 21 mmol) was stirred into 2-amino-5-diethylaminopentane (20
ml, 25 g, 155 mmol) and heated to 135 oC for 16 hours. The excess solvent was distilled
off using a short-path distillation apparatus and distilling up to 120 oC at 0.05 atm,
leaving a brown residue. The residue was separated on silica preparative TLC plates with
an eluent mix of CHCl3:MeOH:NH4OH in 5:1:0.2 ratio, respectively. The product was
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found in a clear band at Rf =0.6. The bands were collected, extracted off the silica with
the eluent solvent mix, and the solvent was evaporated, yielding a dark oil. The oil was
further purified on a silica column using a CHCl3 (with 2% Et3N )/MeOH (with 2% Et3N)
gradient to 30% MeOH (with 2% Et3N ), yielding PL360 (0.01 g, 0.4 mmol, 0.2%).
HPLC (Method 2) tR=1.45 min (99% pure). MS(ESI): m/z=236.21203 (M+). 1H NMR δ
(ppm)(600 MHz, CH3OH-d4): 1H NMR δ (ppm)(CH3OH-d4): 7.84 (2 H, d, J = 5.80 Hz),
6.42 (2 H, dd, J = 5.55, 1.55 Hz), 3.45-3.51 (1 H, m), 2.46 (4 H, q, J = 7.22 Hz), 2.37 (2
H, d, J = 7.84 Hz), 1.40-1.50 (5 H, m), 1.09 (3 H, d, J = 6.40 Hz), 0.93 (6 H, t, J = 7.20
Hz).

13

C NMR δ (ppm)(CH3OH-d4): 155.9, 149.2, 108.6, 53.6, 49.6, 49.6, 48.4, 47.8,

47.8, 35.5, 23.7, 20.7, 20.7, 11.1.

PL350: 4-[2-(4-Benzhydryl-piperazin-1-yl)-ethylamino]-pyridin-3-ol
PL343 (0.22 g, 0.53 mmol) was dissolved in MeOH and evaporated onto neutral
Alumina. FeCl3 (0.23 g, 1.4 mmol) and hydrazine monohydrate (2.5 mL, 2.4 g, 48.5
mmol ) was ground into the alumina. The alumina was loaded into a microwave vial and
heated at 130% for 10 minutes. The mixture was cooled, slurried in EtOAc and filtered
through Celite. The EtOAc was evaporated down to a thick oil. The oil was brought up
in dry THF and added dropwise into a boiling solution of dry THF (10 mL) with isoamyl
nitrite (0.1 mL). The solution was stirred and refluxed for 4 hours, then evaporated down
to oil and purified on an alumina column with EtOAc/MeOH gradient, yielding the
hydroxide side product (mass not recorded ). HPLC (Method 2) tR=7.59 min (92% pure).
MS(ESI): m/z=388.29800 (M+).
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PL364: 4-Amino-1-[2-(4-benzyl-piperazin-1-yl)-acetyl]-pyridinium chloride
Piperazine (13.07 g, 152 mmol) was dissolved in DCM (50 mL) and benzylbromide (6
ml, 8.7 g, 50 mmol) was added in dropwise; the solution was stirred at room temperature
for several days. The reaction mixture was washed with water (6x, 300 mL total) and
then the solvent was evaporated, yielding a white solid. The entire amount of solid and
K2CO3 (7.63g, 55.2 mmol) were stirred together in DMF (50 mL), then PL170 (5.93 g,
28.6 mmol) was added and the mixture was stirred at 40 oC for 16 hours. The reaction
was cooled and filtered. The solvent was evaporated and the residue was purified on a
basic alumina column with CHCl3 eluent, yielding PL364 (0.58 g, 1.7 mmol, 5.9%).
MS(ESI): m/z=311.18743 (M+). 1H NMR δ (ppm)(600 MHz, CH3OH-d4): 1H NMR δ
(ppm)(CH3OH-d4): 8.42 (2 H, dd, J = 5.11, 1.62 Hz), 7.71 (2 H, dd, J = 5.05, 1.62 Hz),
7.33-7.36 (4 H, m), 7.29-7.29 (1 H, m), 3.59 (2 H, s), 3.25 (2 H, s), 2.63 (8 H, br d, J =
35.18 Hz).

13

C NMR δ (ppm)(600 MHz, CH3OH-d4): 13C NMR δ (ppm)(CH3OH-d4):

171.8, 150.9, 147.5, 138.4, 130.8, 129.4, 128.5, 115.2, 63.9, 62.9, 54.1, 53.8.

PL373: 2-(4-Benzhydryl-piperazin-1-yl)-ethylamine
Diphenylmethylpiperazine (1.31 g, 5.2 mmol), bromoethylphthalamide (1.29 g, 5.1
mmol), K2CO3 (1.21 g, 8.8 mmol), and KI (.95 g, 5.8 mmol) were slurried in acetonitrile
and microwave heated to 100 oC for 30 minutes. The reaction mixture was cooled,
diluted with CHCl3 and filtered. The CHCl3 was evaporated leaving a thick oil. The oil
was stirred in MeOH and a white solid precipitated, which was filtered and air dried. The
white solid was slurried in EtOH. Hydrazine monohydrate (27 mL) was added and the
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mixture was refluxed for 8 hours, then cooled to room temperature and filtered. The
EtOH was evaporated yielding PL373, which was used without further purification.

In vitro drug susceptibility assays63
Both CQS (D6) and CQR (Dd2) P. falciparum maintained continuously in culture were
used.103 Asynchronous cultures were diluted with uninfected RBCs and complete
medium (RPMI-1640 with 0.5% Albumax II) to achieve 0.2% parasitemia and 2%
hematocrit. In 96-well microplates, CQ (positive control) or RCQ diluted in complete
medium from 10 mM stock in DMSO were added to the cell mixture to yield triplicate
wells with drug concentrations ranging from 0 to 10-4 M in a final well volume of 100
µL. After 72 h of incubation under standard culture conditions, plates were harvested and
read by the SYBR Green I fluorescence-based method103 using a 96-well fluorescence
plate reader (Gemini-EM, Molecular Devices), with excitation and emission wavelengths
at 497 and 520 nm, respectively. The fluorescence readings were plotted against
log[drug], and the IC50 values were obtained from curve fitting performed by nonlinear
regression using either Prism (GraphPad) or Excel (Microsoft) software.
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